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ABSTRACT 
The thesis entitled "Analysis of Certain Cardiovascular drugs in drug 
formulations" is comprised of five chapters. The first chapter describes a general 
literature survey of the subject matter. The very relevant matters include a brief 
discussion on analytical chemistry, its role played in the field of pharmaceutical and 
biomedical analysis; various types of analytical techniques v^hich are frequently used 
in the field under discussion; the validation of the developed method and the 
slatisticai treatments adopted during the data analysis to ensure and enforce the 
\alidily of the method. 
It is well known that the human nature is the most cautious in every era of the 
development. This lead to the birth of analytical chemistry as it deals with the study of 
ihc intrinsic properties of the materials to discover their applicability or to warn the 
coiiccrncd one \\ ilh the possibility of harm from them. Unlike other areas of studies in 
scicnce there are different properties, which heavily influence the results of the 
analytical methodology at each and every step; thus having direct impact on the 
K-suhs. I hcsc important properties have been discussed. With the passing time, the 
demands ol' ihc biochemical sciences and the advancement of the physical sciences 
opened the door of sophisticated instrumentation in the field by analytical chemistry. 
1 he dilTerenl ivpes of well-established analytical techniques have been discussed. 
Before or during the development of a method, it is necessary to be very 
careful of certain important things. These concepts have been discussed briefly. Once 
the analytical method is advent, it is necessary to decide its suitability for the intended 
purpose. This is known as the method validation. Brief discussion of the validation, its 
components and the different international organization involved in it, has been 
presented. When deciding for the validation of the method, the role of statistical 
analysis can not be ignored. It is the only way to get the most conclusive results from 
the mathematical data obtained during the analysis. It also helps to decide with the 
progress of work at each step. A detailed discussion of the statistical analysis has been 
given. A brief literature and classification of the concerned pharmaceuticals have also 
been presented. 
Second chapter described three simple spectrophotometric methods for the 
determination of amlodipine besylate in pure form and in pharmaceutical 
formulations. The first two methods, i.e. A and B, are based on the oxidation of the 
drug with Fe(III) and the estimation of Fe(II) produced after chelation with either 
1,10-phenanthroline or 2,2'-bipyridyl at 500 and 515 nm, respectively. The Beer's 
law was obeyed in the concentration ranges of 2 - 10 and 4 - 14 ^g mL"' with molar 
absorptivity of 2.9 xlO'* and 2.7 xlO'* L moP' cm"' for methods A and B, respectively. 
The third procedure depends on the interaction of amlodipine besylate with 
ammonium heptamolybdate tetrahydrate, which resulted in the formation of 
molybdenum blue {Xmax 825 nm). The linear dynamic range and the molar 
absorptivity values were found to be 1 5 - 5 9 |ig mL"' and 1.8 xlO'* L moP' cm"', 
rcspectivci). fhc results of the proposed procedures were validated statistically and 
compared with those obtained by the reference method. The proposed methods were 
applied successfully to the determination of amlodipine besylate in commercial 
tablets. 
Third chapter deals with a simple, sensitive and economical method for the 
determination of labetalol hydrochloride. The method is based on the reaction of 
labetalol with sodium nitroprusside and hydroxylamine hydrochloride in sodium 
dihydrogen phosphate - sodium hydroxide buffer solution of pH 12. The green - blue 
colour produced due to the formation of a nitroso derivative has been measured at 695 
nm. The Beer's law was obeyed in the concentration range of 2 - 51 ^g mL"' with 
molar absorptivity of 0.48 x 10'* L moP^ cm~^ Rigorous statisical analyses were 
performed for validation of the method. A detailed investigation of the selectivity of 
the method has been done and was found to be highly selective for the determination 
of labetalol hydrochloride in the presence of its acidic degradation product and 
common excepients of formulations. The proposed method was successfully applied 
to the determination of labetalol hydrochloride in the laboratory prepared dosage 
forms. Comparison of the means of the proposed procedure with a reference method 
using point as well as interval hypotheses showed no statistically significant 
difference. The developed method was extended to investigate the possibility of its 
applicability in biological samples. 
Fourth chapter described two simple and sensitive spectrophotometric 
methods for the assay of lisinopril in pure form and pharmaceutical preparations. The 
first method is based on the reaction of the drug with ninhydrin in N,N'-
dimethylformamide (DMF) medium at room temperature which is followed 
spccirophotometrically by measuring the increase in absorbance at 595 nm as a 
function of time. The initial-rate, rate-constant and fixed-time (at 10 min) procedures 
arc utilized for constructing the calibration graphs to determine the concentration of 
the drug. The initial-rate and fixed-time procedures show a linear response over the 
concentration range 10-50 i^g mL ' whereas rate-constant procedure is applicable in 
the range 10-40 ^g mL~'. In the second method, the drug reacts with ascorbic acid in 
DMF medium resulting in the formation of a coloured product, which absorbed 
maximally at 530 nm. Beer's law is obeyed in the concentration range of 5-50 i^g 
mL"' of lisinopril with molar absorptivity of 4.548x10^ L mor'cm"'. The variables 
affecting the development of the colour are optimized and the developed methods are 
validated statistically and through recovery studies. The proposed methods have been 
successfully applied to the determination of lisinopril in commercial tablets. 
The last chapter includes a simple, sensitive and economical simultaneous 
volumetric and spectrophotometric methods for the determination of captopril. The 
methods were based on the reaction of captropril with potassium iodate in HCl 
medium. Amaranth was used as indicator to detect the end point of the titration in 
aqueous layer. The iodine formed during the titration was extracted into CCI4 and 
subsequently determined spectrophotometrically at 510 nm. The Beer's law was 
obeyed in the concentration range of 120-520 |ig mL~'. Rigorous statistical analyses 
were performed for the validation of the proposed methods. The proposed methods 
were successfully applied to the determination of captopril in dosage forms. 
Comparison of the means of the proposed procedures v^th those of reference methods 
using point and interval hypothesis tests showed no statistically significant difference. 
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C l j a p t e r I 
Thanks to that great fore-sightedness of Aristotle which threw the Hght of 
inteUigence over the dark cover of preconcieved ideas of mysterious forces behind the 
effects of biochemicals inside the body. He anticipated the nature of hormones and 
gave birth to a very diverse concept of science, that is, the Chemical Science. The 
renowned astronomer and the physicist Galileo, suggested that in order to understand 
the universe, man must pay attention to the quantitative aspects of his surroundings 
and discover the mathematical relationships that exist between them. These two 
unbeatable suggestions by the father of chemical science, Aristotle, and the founding 
father of the modem science, Galileo, not only highlighted the importance of the 
chemical as well as the mathematical science but also given a strong platform to the 
whole scientific world to grow for the welfare of our fascinating fauna and enchanting 
flora. Though first 350 years of the "modern age" made only the fascinating 
anecdotal readings and thus misleading in view of the scientific concepts, the 
succeeding continuous efforts of the scholars made the Chemistry a highly diversed 
leading science, sometimes called as Central Science, as can be seen occupying top 
position in Fig. 1.1. 
The causes of disease are the basic problem associated with the living being 
from the very start of the life on the earth. The way of its removal, i.e. the art of its 
therapy especially dominated by the medicine is an ancient art of human life, though 
its nature is continuously changing in the different era with time. The route of the 
basic medical science can be expected to arise from the studies of the chemical 
sciences. But this is the fact that the medical aspect has given it the real importance in 
the public life. 
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Fig. 1.1: The relationship between analytical chemistry, other branches of 
chcmistr>'. and the other sciences. The central location of 
analytical chemistry in the diagram signifies its importance and the 
breadth of its interactions with many other disciplines. 
The earlier name, pharmaceutical chemistry, reflected the fact that some 
nineteenth century pharmacists were the first to extract and purify naturally occurring 
drugs. Some of the tasks of medicinal chemistry, as we know them today, were 
claimed by biological sciences. S.C.F. Hahnemann (1755 - 1843), the founder of 
homeopathy, believed that the drug solutions should be diluted to the point of 
practically omitting their content of active components because high concentrations of 
drugs produce toxic reactions, hence he called it as "Similia Similibus Curantur". 
Samuel Thomson (1769 - 1843) stated, "all diseases are the effect of one general 
cause and may be removed by one general remedy" [1], Louis Pasteur's (1822 -
1895) discovery of pathogenic parasites as the causes of infectious diseases prepared 
the way for healing of such diseases with chemicals and given birth to the 
chemotherapy system. Pharmacologist Buchheim, in 1876, wrote that the mission of 
pharmacology was to establish the active substances within the [natural] drugs, to find 
the chemical properties responsible for their action and to prepare synthetic drugs that 
were more effective [2]. Among the earliest materials known, from medicinal point of 
view, were ch'ang shang in China (2735 B.C.), which was later, identified as the 
antimalarial plant Dichroa febrifuga [3]. During the period regarded as the 
"Quintessence to Chemical" (Paracelsus, 16^ century-Ehrlich, 19'*^  century) [4]. 
people had undergone major gradual change in the use of natural products in their 
entire states (mainly having medicinal importance) to either the purified extracts of 
the material of interest fi"om those or to synthetic chemically-produced materials. 
Around 1890 some hypnotic, antimalarial, anti-inflammatory drugs, and adrenergic 
and cholinergic hormones had been developed, followed by the discovery of 
antibacterial and antibiotics. The post World War-II period had given major 
breakthrough to the drug development and a number of antituberculous agents, the 
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steroid hormones and contraceptives, antipsychotic, anxiolytic and antidepressant 
psycho-pharmacological drugs were discovered. Finally with the enforcement of Pure 
Food and Drug Act by the Food and Drug Administration of the United States, the 
therapeutic research, drug development, introduction and pharmaceutical 
manufacturing entered their "Golden Age" (1940-1960). 
With the cautious nature of human being and growing awareness especially 
for the health hazard reasons, the concept of quality emerged which lead to the 
interest in the work of analysis. With no name designated and no specificity given in 
the old age, analytical chemistry is the important part of the good quality life in 
every period of the development. 
Analytical chemistry is a measurement science consisting of a set of powerful 
ideas and methods that are useful in all fields of science and medicine. Since 
analytical chemistry is a wide-ranging and interdisciplinary subject, so it is not an 
easy task to define it. The late Professor Charles N. Reilley, an eminent analytical 
scientist of the University of North Carolina at Chapel Hill, glibbly stated "Analytical 
chemistry is what analytical chemists do" [5,6]. The Division of Analytical Chemistry 
of the American Chemical Society [7] has given a more detailed definition. 
"Analytical Chemistry seeks ever improved means of measuring the chemical 
composition of natural and artificial materials. The techniques of this science are 
used to identify the substances, which may be present in a material, and to determine 
the exact amount of the identified substances ". 
The importance and significance of analytical chemistry can be cited in the 
literature as old as in the famous novel of Thomas De Quincey, Confessions of an 
English Opium Eater [8], where the man of letters permed that how his surgeon friend 
achieved a uniform method of extracting the opium so as to give a fairly constant 
potency. In a very popular recent example, an exciting illustration of the power and 
significance of analytical chemistry occurred on July 4, 1997 [9], when the Pathfinder 
spacecraft bounced to a halt on Ares Vallis, Mars, and delivered the Sojourner rover 
from its tetrahedral body to the Martian surface. The world was captivated by the 
Pathfinder mission. As a result, the numerous World Wide Web sites tracking the 
mission were nearly overwhelmed by millions of Internet surfers who closely 
monitored the progress of tiny Sojourner in its quest for information on the nature of 
the Red Planet. The key experiment aboard Sojourner used alpha proton X-ray 
spectrometer (APXS), which combines the three advanced instrumental techniques of 
Rutherford backscattering spectroscopy, proton emission spectroscopy and X-ray 
fluorescence. The APXS data were collected by Pathfinder and transmitted to Earth 
for further analysis to determine the identity and concentration of most of the 
elements of the periodic table. The determination of the elemental composition of 
Martian rocks permitted geologists to rapidly identify them and compare with 
terrestrial rocks. The Pathfinder mission is a spectacular example illustrating the 
application of analytical chemistry to practical problems. 
The discipline of analytical chemistry consists of qualitative as well as 
quantitative analysis. The qualitative aspect establishes the chemical identity of the 
species in the sample. Thus, from medical point of view, qualification is an important 
process of acquiring and evaluating data, which establishes the biological safety of the 
individual impurity profile at the levels specified. Thus, the pharmaceutical analyst 
and toxicologist must work hand in hand throughout the pre-chemical and clinical 
development programme in order to be able to set meaningful specification 
requirements. The importance of qualifying impurity profiles is also relevant to th
7 
development scientists to ensure consideration is given to the impurities present in 
batches being used in safety studies, although there are opportunities to carry out 
metabolic studies to help in the qualification processes. 
With the major emphasis on the qualitative aspect of the analytical chemistry 
in the beginning, the revolution came in the quantitative analytical chemistry, thus 
broadening the width of the whole subject. The credit of such a revolution goes to the 
finely defined theoretical aspects of the analytical chemistry by the scholars of the 
modem age as well as the advent and application of the modem sophisticated 
analytical instrumentations. 
The present generic objective of the analytical chemistry is to get the high 
quality analytical information by expending minimum material, less time with least 
number of the man-power and minimum risks at the lowest cost of expense. The 
quality in the analytical results is seriously influenced by three different analytical 
properties. These are capital properties (accuracy and representativeness); basic 
(sensitivity, selectivity, precision and sampling) and accessory properties 
(expeditiousness, cost-effectiveness and personal related considerations like personal 
safety and comfort). The capital properties are associated with the consistency in the 
results, thus helpful in deciding the quality of the results obtained. But these are basic 
properties, which arc mainly responsible for the quality in the output, thus deciding 
the capital properties. The accessory properties, though seems to be less significant, 
but often have major practical implications and some times affect the results heavily. 
The hierarchy of these important components has been presented in Fig 1.2. 
Goals Quality Properties 
Fig. 1.2. Goals of analytical chemistry and their relationships to 
the analytical quality and analytical properties. 
The pharmaceutical analysis always needs for the sensitive and sophisticated 
techniques. The most frequently used analytical techniques in pharmaceutical analysis 
are titrimetry, chromatography, electrochemical analysis and spectroscopy. 
Sometimes these techniques are combined with other supporting/subsidiary 
instruments like flow injection analysis system or kinetic type of analysis; thus 
making them more sensitive, selective and fast. 
In the field of drug analysis, volumetric methods, either direct or indirect, have 
their own importance due to their inherent simplicity. This is the reason why still a 
large number of official methods for the determination of pharmaceuticals in the 
pharmacopoeias are based on titrimetry [10-12]. Though it is the oldest technique in 
the market now but still having their recognition in the field of scientific research. 
However, there is no doubt that most analyses are now performed by instrumental 
methods. 
Electrochemical methods are characterised by high sensitivity, selectivity and 
accuracy. Pharmaceuticals containing phenolic, amino, heterocyclic nitrogen, ketonic 
or aldehyde group undergo oxidation at their characteristic potentials and hence 
selectivity of the technique is increased. Important electrochemical techniques such as 
amperometry, conductometry, potentiometry, anodic and cathodic stripping 
voltammetry, differential pulse voltammetry and polarography have been used in drug 
analysis [13]. Ion-selective electrodes are electrochemical sensors that allow 
potentiometric measurements of the activity of particular species in aqueous and 
mixed solvents, or partial pressures of dissolved gases in water [14]. Potentiometric 
titrations are also reported in the pharmacopoeias as the standard method for the 
determination of certain drug substances [15-17]. Despite the wide use of 
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spectrometry and chromatography, analysts are choosing polarography and 
voltammetry due to their sensitive and characteristic qualitative as well as quantitative 
nature of analysis. Bersier has reviewed the importance of these techniques in 
pharmaceutical analysis [18], 
Chromatographic methods have their ovm importance in the field of trace 
analysis and sometimes prove it as the only way. The different kind of it like paper 
chromatography, thin layer chromatography, column chromatography, capillary 
electrochromatography, high performance thin layer chromatography, high 
performance liquid chromatography and gas chromatography, have most frequent 
applications in the field of pharmaceutical as well as the biomedical analyses. Thin 
layer chromatography (TLC) is a simple, in-expensive and rapid technique, having 
wide applications for the separation and identification of impurities and degraded 
products [19]. Capillary electrochromatography (CEC) is a method in which liquid 
mobile phase is driven through a stationary phase in a packed capillary column by the 
electro-osmotic flow generated by a large difference in potential across the column 
[20-23]. CEC previously has been utilised for the separation of certain 
pharmaceuticals; an interesting example is that of a diastereoisomcric mixture not 
successfully separated on a chiral HPLC column [24], which clearly shows its 
considerable advantage. Among all the chromatographic methods, high performance 
liquid chromatography is most acceptable nowadays due to its sensitivity and 
selectivity even in a multicomponent mixture. It is widely used for the identification 
of drugs in plasma and dosage forms [25-38], and creating its own position in the 
dissolution monographs of pharmacopoeias for the assay of drugs in dissolution fluids 
[39, 40], 
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Spectroscopic methods are widely used for the assay of drugs in 
pharmaceutical formulations. The most commonly used spectroscopic techniques for 
quantitative analysis are ultraviolet (UV) and visible methods. UV-spectrophotometry 
is best known and most widely applied in structure identification and quantitative 
analysis. It has become an established and fundamental technique in pharmaceutical 
research and analysis as well as in the broad area of organic and inorganic analysis. 
Endriz [41] has described an UV-spectrophotometric method for the determination of 
heroin hydrochloride, methapyrilene hydrochloride, and quinine hydrochloride 
mixtures. The spectra for heroin, methapyrilene, and quinine show points of 
maximum absorption at 280 nm, 313 nm and 348 nm, respectively. Methapyrilene 
and quinine do not seriously interfere with the heroin maximum, and methapyrilene in 
dilute acid solution absorbs only slightly at the quinine maximum of 348 nm. The 
procedure is fast and accurate enough for forensic purposes. Analyses of 
chloramphenicol and tetracycline hydrochloride [42] and phenobarbital and 
pentobarbital in pharmaceutical formulations [43] are further examples of the utility 
of UV-spectrophotometry in this area. Because of the sensitivity of the UV method, 
the amount of sample required for the spectral identification is very small; drug levels 
and metabolites have been determined in biological tissues and fluids after separation 
and extraction. Since most materials are not photosensitive, the technique is non-
destructive, and the metabolite or drug can be recovered for further testing. However, 
these methods are inadequate in the presence of other components (like any drug of 
combination, excepients or decomposition products) showing similar UV spectra [44]. 
Photocolourimetric methods of analysis are performed in the visible 
region of light. They are based on the measurement of the absorbance of the 
coloured compounds. Usually, the analyte being colourless, they are reacted 
with the suitable chemical reagents in order to convert them in coloured 
compounds. Simple colourimetric and UV methods continue to be popular for 
carrying out single-component assays on a variety of formulated products. 
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Representative examples [45-82] of some of the many assays that have been 
published are given in Table 1.1. 
In the course of this discussion, the importance of computer-aided 
spectrophotometric determination of multicomponent systems can not be ignored. The 
quantitative spectrophotometric analysis of active ingredients in a solution containing 
more than two substances can be difficult to achieve by means of the traditional 
methods. In order to resolve this problem, several papers were published on the 
application of least squares method and orthogonal polynomials for the analysis of 
multicomponent systems [83-88]. 
Diflerencc spectrophotometry is an important and useful technique used in the 
determination of medicinal substances by eliminating specific interference from the 
degradation products, co-formulated drugs and non-specific irrelevant absorption 
from the formulation matrix. The technique involves reproducible alterations of the 
spectral properties of the absorbance difference between two solutions, provided that 
the absorbance of the other absorbing substance is not affected by the reagent(s) used 
to alter the spectral property [89]. 
Derivative spectrophotometry is an analytical technique of great utility for 
both qualitative and quantitative information from specfra composed of unresolved 
bands. It was introduced more than thirty years ago [90-92] for resolving two spectral 
lines of very nearly equal wavelength. To accomplish this resolution, the first or 
second derivatives of an intensity signal were obtained electronically as a fiinction of 
time, wherein wavelength was changed linearly with time. The result was a signal 
similar to the first or second derivative of intensity with respect to wavelength, thus 
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measuring the slope or curvature in the intensity distribution. A measurement of slope 
or curvature focused on the more subtle characteristics of the overlapping spectral 
lines, and thus the two unresolved lines could be separated. It has advantages for the 
solution of specific analytical problems. The derivative method has found applications 
not only in the UV-visible spectrophotometry, but also in infrared [93], atomic 
absorption [94] flame emission spectrometry [95] and fluorimetry [96, 97]. The use of 
derivative spectrometry is not restricted to special cases, but may be of advantage 
vs^henever quantitative study of normal spectra is difficult. Its disadvantage is that the 
differentiation degrades the signal-to-noise ratio, so that some form of smoothing is 
required in conjunction with the differentiation [98]. 
Even though many pharmaceuticals show native fluorescence, there is also an 
important group of compounds, which is not fluorescent, can be determined by using 
fluorescent probes through derivatisation reactions. An account of the fluorescent 
probes more widely used for the determination of drugs and related compounds have 
been reviewed [99]. 
Chemiluminescence is a powerful tool for drug analysis since its detection 
limits are extremely low, its instrumentation is very simple and of low cost. It has a 
wide range of applications with increased sensitivity. The excellent sensitivity and the 
versatility of the chemiluminometric methods of analysis are the main reason for the 
recent surge of interest in chemiluminescence. Certain drugs have been analysed 
based on the phenomenon of chemiluminescence in liquid phase [100-102]. 
In the recent period, analysts are much interested in coupling the 
chromatographic techniques with spectrometric techniques. The advent of liquid 
chromatography with mass spectrometry, gas chromatography with tandem mass 
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spectrometry and liquid chromatography-electrospray tandem mass spectrometry are 
good examples. Hirsch et. al. have determined the antibiotics using chromatography-
electrospray tandem mass spectrometry[103]. Dielectric relaxation spectroscopy and 
x-ray powder diffractometry are also utilised for the identification of pharmaceuticals 
[104,105]. The safety of a drug product is dependent not only on the toxicological 
properties of the active drug substance itself, but also on the impurities that it 
contains. Monitoring of drug substance's impurities is routinely accomplished using 
HPLC. However, HPLC retention times can vary, resulting in vmcertainty as to 
whether a peak at a new retention time is a new impurity. Because standards of the 
minor impurities (less than 0.1% by area) are not usually available, some method is 
needed to characterise each of these peaks without isolating them. This on-line 
characterisation might be accomplished using UV diode array spectral matching 
[106]. 
Flow injection analysis (FIA) is characterised by its simplicity, speed and the 
use of in-expensive equipment. In FIA, as a general principle [107-110], a quantity of 
accurately measured dissolved sample is injected or introduced into the carrier stream 
flowing through the system tubing, with or without additional changes like chemical 
reaction etc., occurring between the sample and the carrier. As the analyte (or its 
reaction product) passes through the continuous detector, a transient signal is 
generated and recorded. Therefore, FIA has certain clear advantages like (i) reduced 
reagent consumption [111]; (ii) high sampling frequency [112]; (iii) safety in applying 
toxic reagents because the whole analysis proceeds in a closed system; emd (iv) 
increased selectivity when the analyte is accompanicd by more slowly reacting 
components. This technique has been utilised successfully in the determination of 
some compounds of pharmaceutical interest [13,113,114]. In the recent years, 
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analytical techniques such as atomic absorption and emission spectrometry are also 
frequently used in the field of pharmaceutical analysis [115-117], 
Impurities present on the particle surfaces, e.g. from residual mother liquor, 
may be low in terms of percentage but they may change in a significant way the 
behaviour of the powder in the manufacturing process or in the final medicinal 
product. Therefore, a methodology is needed to detect such deficiencies at the 
surfaces or in the upper layers of the powder. Spectroscopic reflectance technique of 
sufficient sensitivity and precision could be of help to discriminate between 
apparently identical materials from different sources or to detect inconsistencies 
between the batches from the same source. 
Near infrared (NIR) spectroscopy is a technique which has found its way into 
pharmaceutical control laboratories in recent years for raw material identification, 
water analysis and other pharmaceutical analyses [118-123]. Nuclear magnetic 
resonance (NMR) spectroscopy is a well-known spectroscopic technique specially 
used for the qualitative characterisation of the chemicals. In the recent attempts, NMR 
is also used as a sensitive quantitative method; a mini review has been presented in 
this context [124]. Moreover, NMR spectroscopy is favoured by chemists as a 
powerful technique for molecular structure determination. 
Whenever the question of mathematical and statistical treatments arises, the 
role of chemometrics can not be ignored. Chemometrics is defined as "the chemical 
discipline that uses mathematical, statistical and other methods of formal logic to 
design or select optimal procedures and experiments, and provide maximum chemical 
information by analysing chemical data" [125,126]. Chemometrics is the science that 
helps to make good use of information technology in the chemical analysis and to 
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develop intelligent analysers, i.e. that automatically select the correct method for a 
given problem, carry it out, validate it and interpret the results. Typical applications of 
chemometric methods are the development of quantitative structure-activity 
relationships or the evaluation of data from chemical analysis. 
Kinetic methods of analysis, which are in fact, the study of the measurement 
of concentration changes (detected via signal changes in a reactant, which may be the 
analyte itself) with time after the sample and reagents have been mixed. They are not 
only the good choices for the drug analysis but very relevant to analytical chemistry in 
at least four respects: (a) it allows the elucidation of the physical, chemical and 
physico-chemical mechanisms on which analytical processes are based and hence 
their rational optimisation; (b) it facilitates the development of new analytical 
methods and techniques that are otherwise unattainable if the dynamic aspects are not 
dealt with; (c) it is the foundation of reaction rate methods (kinetic determinations); 
and (d) it contributes as sensitivity, selectivity and precision. The principles and 
applications of the kinetic methods have been reviewed [127-129]. Kinetic methods 
are generally rapid, reproducible and involve simple instrumentation. Though there 
are different modes of calibration in kinetic method, but the reaction rate methods 
involve two general aspects, which endow them with higher selectivity than 
equilibrium methods, namely the scarcity of parasitic blank signals and the possibility 
of using kinetic discrimination. In case of very fast reactions, the automatic handling 
is preferred for better and more accurate results; so the automation of the 
instrumentation is required. They can also be used to enhance the reproducibility and 
rapidity of slow reactions. Since kinetic methods of analysis require accurate timing, 
careful control over experimental conditions, precise sample and reagent preparation, 
proportioning and mixing, and accurate measurements of dynamic signals, hence they 
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are well suited to intelligent automation. Kinetic automatic techniques are generally 
based on open systems, among the most popular of which are stopped flow (SF) 
system [130] and the continuous addition of reagent (CAR) technique. Several drugs 
have been determined by using the CAR technique [131-134] with photometric 
[135,136] and fluorimetric detection [137]. On the other hand, the CAR technique has 
been extended to chemiluminescence (CL) reactions as CAR chemiluminescence 
spectrometry (CARCL), a new approach, which have proved outstanding for the 
analysis of drugs and other substances of analytical interest. The use of catalysts to 
accelerate analytical reactions is feasible with both reaction rale and equilibrium 
determinations. In this concern, the use of micellar media in kinetic methods is 
recently encouraged to enhance the rate of reaction (through micellar catalysis) which 
in turn reduces the time of analysis and also improves the sensitivity and selectivity 
[138-141]. Multicomponent kinetic determinations, often called as differential rate 
methods, are also receiving a good deal of current attention in research laboratories. 
The various approaches to multicomponent determinations have been reviewed 
recently by Perez-Bendito [142]. One new approach that has been proposed for 
dealing with overlapping spectra is the kinetic wavelength-pair method [143]. For a 
mixture of two components, the method relies on measuring the difference in the rate 
of change of absorbance with time at two pre-set wavelength pairs (four 
wavelengths). Another method called as the H-point standard addition method [144] 
proposed by Bosch-Reig et al. is capable of kinetic determination of components with 
overlapping spectra in their binary mixture. 
From the manufacturing to the packaging stage, a number of sources are there 
which cause impurification of the product. Such impurities may be organic or 
inorganic type, or the residual solvents used to create the desired crystal morphology. 
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the trace of starting materials remaining unreacted, the remaining intermediate or bye-
products, reagents £ind catalysts etc. Usually pharmaceuticals are very sensitive to the 
style of storage and class of packaging that ultimately causes degradation of the actual 
products. Unlike other consumable products in the daily life, any abnormality in the 
recommended dosage amoxmt of a pharmaceutical compound or the presence of 
impurity may show adverse toxicological effects. 
Once the pharmaceutical product is produced in bulk or prepared and supplied 
in the commercial form, very crucial questions arise that whether the manufactured 
product is pure or impure; is the supplied form is as per the requirement; and so many 
similar other questions threatening the one associated with it, i.e. analytical chemists. 
The ignorance of such crucial questions may be life threatening to one expected to be 
associated with it. The efforts of analytical chemists and the role of analytical 
techniques are the only way to answer these questions. They are responsible to satisfy 
everyone from the manufacturing industries to the market. 
As mentioned above, the safety of drug products are dependent not only on the 
toxicological properties of the active drug substances itself but also on the impurities 
that it contains. The requirements of quality, quantity, purity and safety of 
pharmaceutical formulations warreints a careful thought by every one associated with 
this area. Due to easy availability of sub-standard drugs and medicines in the markets 
of the developing countries, it is crucial to assay drugs in dosage forms. Hence 
development of rapid, simple and cost-effective analytical methods for the analysis of 
drugs are the need of the day in public defence. 
The increasing emphasis on the pharmacokinetic, bioavailability and 
therapeutic monitoring of drugs has placed a heavy burden on drug analysts. Reliable 
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measurements of very low levels of drugs in complex matrices are frequently 
required. Because of the vast number of drugs introduced every year, more and more 
methods for drugs and metabolite determination are being developed either for routine 
or research use. Analytical procedures are used throughout the drug development and 
the manufacturing of drug substances and drug products. Important decisions such as 
the establishment of the shelf-life from stability studies, the need for additional 
toxicological trials, if new impurities appear or if known impurities exceed the 
qualified levels, the reworking of batches or batch release or rejection are based on 
analytical results. In order to make the right decisions and to avoid additional work, 
an appropriate performance of the analytical procedure is essential and this needs the 
"suitability of the method for its intended use ". 
The overall responsibility of an analytical chemist does not reach to its end 
here. Once a method is developed for the determination of a pharmaceutical product, 
another question, not less crucial than the previous one, arises, i.e., is the developed 
method reliable; may it guarantee the quality produced as per the requirement. If yes, 
how? 
For a number of years analytical chemists in the field of pharmaceutical and 
biomedical analysis have learned how to demonstrate that their methods have a 
performance that can guarantee reliable results. After the advent of good laboratory 
practice (GLP), we know this exercise as validation of analytical methods. 
Once an analytical method is advent, it is important to validate the method 
before it should be recommended for the routine analysis. Method validation of 
analytical procedure, i.e. the proof of its suitability for the intended purpose, is an 
important component in determining the reliability and reproducibility of the methods 
and is required for any regulatory submission. The method should be defensible with 
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respect to regulatory requirements and reliable by incorporating statistical analysis to 
evaluate its performance. Validation of analytical methods has been the subject of 
discussion in recent years [145-148]. The procedure of validation requires the 
calculation and fitting of the experimental data within the standard fixed criteria. 
Statistical techniques are used to evaluate the linearity, precision, accuracy, 
robustness/ruggedness, sensitivity (limit of detection and quantitation) and specificity 
etc. Other aspects needing to be considered include identification and handling of 
samples prior to analysis, stability of samples under various storage conditions and 
the continuous assessment (quality control) of the method during its routine use. 
Before an analytical method is used for routine analysis it must be demonstrated first 
that the method fulfils certain performance criteria, when this has been documented, 
the method is said to be validated. 
There are several international organisations and regulatory authorities which 
are involved in fixing the criteria for the validation. Some of them are listed below 
(Table 1.2). In the field of drug analysis, it is very clear that the definitions cover the 
entire field of analytical chemistry from bioanalysis to substance and product analysis. 
Those specifications which are generally accepted for validation include (i) 
method selectivity/ specificity, (ii) sensitivity (limit of detection and quantitation), 
(iii) linearity (relationship between the response and concentration), (iv) accuracy, (v) 
precision, (vi) recovery and (vii) robustness/ruggedness. 
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Tabic 1.2. Validation of analytical methods - international definitions. 
Organisation Applicability Remarks 
lUPAC Worldwide 
ILAC Worldwide 
WELAC Europe 
ICH Europe, Japan, USA Only pharmaceutical products. 
ISO Worldwide Lacks definitions of selectivity and 
specificity. 
Abbreviations; lUPAC, International Union of Pure and Applied Chemistry; ILAC, 
International Laboratory Accreditation Conference; WELAC, Western European 
Laboratory Accreditation Co-operation; ICH, International Conference On 
Harmonisation; ISO, International Organisation for Standardisation. 
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Before proceeding for the advent of a validated analytical procedure, an 
authenticated analytical reference must be available to prepare the standard reference 
solution. The actual nature of the compound, i.e. whether it is a free base or salt 
should be known. The stability of the compound should be continuously monitored to 
exactly know the duration of its use. It must be continuously checked for any 
contamination or impurity. The optimum conditions of the method to be proposed 
must be optimised with respect to the various aspects/variables like the suitable 
amount of the standard reference to be used for the optimisation process, actual 
sufficient amount of different reagents, the enough time for the completion of the 
analytical reaction, the suitable extractant, extraction schemc and the actual volume of 
the extractant to be used in order to remove the interferents, the right \say to store the 
analyte under consideration and an appropriate sampling for enhanced 
representativeness. These can be regarded as the prerequisites of the validation. 
The International Conference on the Harmonisation of the Technical 
Requirements for Registration of Pharmaceuticals for Human Use has harmonised the 
requirements in two guidelines [149,150]. The first one summarises and defines the 
validation characteristics needed for various types of test procedures; the second one 
extends the previous text to include the experimental data required and some 
statistical interpretation. These guidelines serve as a basis world-wide, both for 
regulatory authorities and industry and bring the importance of a proper \'alidaiion to 
the attention of all those involved in the process of submission. In order to fulfil the 
validation responsibilities properly, the background of the validation parameters and 
their consequences must be understood. 
Detection limit (DL) is the lowest amount of analyte that can be detected, as it 
(the analyte) yields instrumental response greater than a blank, but cannot be 
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quantified. It is a parameter of "limit test" and expected to produce a response, which 
is significantly different from that of a blank. On the other hand, quantitation limit 
(QL) is a parameter of "determination test" and can be defined as the lowest 
concentration of analyte that can be measured and quantified with acceptable 
precision and accuracy. Hence, it is the lowest concentration included in the standard 
curve and is used to interpolate unknown sample concentration. One should be aware 
that the determined QL (or DL) is strongly related to the equipment actually used as 
well as to the time of determination. They may represent more system parameters than 
characteristics of the analytical procedure. In cases where a general QL is required, as 
in pharmaceutical analysis, it is essential to define a realistic QL (or DL) for the 
analytical procedure, independently from the equipment used, because this limit has 
important consequences (e.g. for the reporting threshold for impurities or for method 
transfer). 
DL and QL can be calculated from the standard deviation of the blanks. This 
approach is usually performed with instrumental methods. Measuring a blank sample, 
the standard deviation is calculated from the numerical outputs. DL and QL are 
defined as the 3.3 and 10 fold, respectively, of the standard deviation of the blank. 
The values are converted to a concentration by the slope of a corresponding 
calibration line [150], 
b b 
If calibrations are used to quantify the analyte, the intercept can be regarded as 
an extrapolation of a blank determination. DL and QL are defined as the 3.3 and 10 
h b 
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fold, respectively, of the standard deviation of the intercept. The values are converted 
to a concentration by the slope of a corresponding calibration line. 
Where Sa is the standard deviation of the intercept and b is the slope. 
Calibration range is defined by the expected concentration in the samples, and 
will be usually in the linear range of the detector for that analyte, where the 
determined response is directly proportional to the concentration The calibration 
range should neither be too wide nor too narrow [146]. Least square linear regression 
is normally be used to define the calibration line mathematically. The range of an 
assay method can also be defined as the concentration intervals, over which an analyte 
can be measured with acccplablc precision and accuracy. 
Not all the characteristics included in the validation criteria as mentioned 
above are necessarily required to be demonstrated in every case but the evaluation of 
the linearity of the relationship between the actual analyte concentration and the test 
result from the method, however, is required for quantitation testing for impurities and 
for assay methods [118], The requirement for linearity is independent of the 
technology used to ascertain the analyte concentration. This term holds good for 
analytical methodology from manual wet chemistry to the latest high-tech 
instruments. Linearity is defined as "the ability of analytical procedure (within a given 
range) to obtain test results which are directly proportional to the concentration 
(amount) of analyte in the sample" |149]. In some cases, to obtain linearity between 
assays and sample concentration, the test data may have to be subjected to a 
mathematical transfonnation prior lo the regression analysis, ll means in ease of a 
non-linear relation suitable mathematical function may be used for the linearisation 
process if there is a linear relationship, test results should be evaluated by appropriate 
statistical methods, for example, by the calculation of regression line using the 
method of least square [150]. The requirements and relevant parameters for the various 
calibrations are given in Table 1.3. 
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Table 1,3. Requirements for the different calibration modes with relevant parameters. 
Quantitation Requirements Relevant parameters 
Single Point 
Calibration 
External standard 
Linear Function Standard error of slope (residual standard 
deviation), sensitivities (RSD, graph), residual 
analysis, statistical tests (vs. quadratic regression). 
Non-significant 
ordinate intercept 
Inclusion of zero in confidence intci-val of the 
ordinate intercept, magnitude of the intercept (as 
percent of the signal at 100% test concentration). 
Multiple Point 
Calibration 
Linear, 
Unweighted 
Homogeneity of 
variances^ 
Linear function 
Homogeneity of 
variances^ 
F- tes t of the variances at the lower and upper limits 
of the range. 
Standard error of slope (residual standard 
deviation), sensitivities (RSD, graph), residual 
analysis, statistical tests (vs. quadratic regression). 
F- tes t of the variances at the lower and upper limits 
of the range. 
Linear, Weighted Linear function Standard error of slope (residual standard 
deviation), sensitivities (RSD, graph), residual 
analysis, statistical tests (vs. quadratic regression). 
Non-linear Continuous function Appropriate equation 
100%-method 
(area 
normalisation for 
impurities) 
For main peak: 
Linear function 
Standard error of slope (residual standard 
deviation), sensitivities (RSD, graph), residual 
analysis, statistical tests (vs. quadratic regression). 
Non-significant 
ordinate intercept 
Inclusion of zero in confidence interval of the 
ordinate intercept, magnitude of the intercept (as 
percent of the signal at 100% test concentration). 
Homogeneity of 
variances® 
F-tes t of the variances at the lower and upper limits 
of the range. 
For impurities: 
Linear function 
Standard error of slope (residual standard 
deviation), sensitivities (RSD, graph), residual 
analysis, statistical tests (vs. quadratic regression). 
' May be presumed for a limited range (factor 10 - 20). 
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As per the ICH guidelines, the accuracy of an analytical procedure expresses 
the closeness of agreement between the value, which is accepted either as a 
conventional true value, or an accepted reference value, and the value found [149]. 
There are different approaches to confirm the accuracy of a method like comparison 
of the proposed method with another one, from the recovery data, by the linearity 
method etc. The comparison of two analytical procedures can be performed using a 
^test. It must be verified beforehand, whether the scattering of both data sets is of a 
comparable magnitude (homogeneity of variances, F-test). If reference substance is 
available, the mean obtained with the proposed analytical procedure is tested versus 
the known or declared content. However, the absolute magnitude of the difference 
should also be taken into consideration. Alternatively, an acceptable difference can be 
defined as acceptance criteria, or a statistical equivalence test can be applied. For 
both methods of comparison, it must be taken into consideration that two independent 
analytical procedures most probably differ in their specificity. This might lead to a 
systematic influence on the results. If the effect can be quantified, the means should 
be corrected before performing the statistical comparison. If a correction is not 
possible, the presumptions of the statistical test are violated and the /-test should 
consequently not be performed. 
The lack of interferences between the matrix (placebo) and the analyte, 
adsorption vsithin the equipment, incomplete extraction of the analyte during the 
sample treatment, degradation etc. can be verified by spiking known amounts of the 
analyte to the matrix (placebo). For example, drug substance is spiked to placebo 
(reconstiluied drug product) or impurities / degradants are added to drug substance or 
drug product and are subsequent analysed. This should be performed as near as 
possible to the authentic conditions. Ideally, the drug product is prepared with 
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different contents of active ingredient. The least authentic approach would be the 
addition of standard stock solutions to a placebo solution. By spiking at different 
concentration levels, the recovery can be calculated either at each level separately as a 
percent recovery, or as a linear regression of the found concentration versus the added 
concentration (recovery function). In the case of the percent recovery it can be tested, 
whether the recovery mean differs significantly from the theoretical value 100 % (e.g. 
by inclusion of 100 within the 95% confidence interval). However, the absolute 
magnitude of the difference should also be taken into consideration, especially with 
respect to impurities in low concentration ranges. Alternatively, an acceptable 
difference to 100% can be defined as acceptance criteria, or a statistical equivalence 
test can be applied. With respect to the recovery function, the slope and intercept can 
be tested versus the theoretical values of 1 and 0 (by their 95% confidence intervals) 
or versus acceptable limits for deviation. Due to the different weighting effects, the 
two approaches might lead to different results. The procedure should be selected as a 
function of the quantitation method. The single-point calibration represents a 
normalisation procedure; therefore the percent recovery is better suited. The recovery 
function is indicated if a multiple-point calibration is used. It is absolutely essential 
that the accuracy be validated with the same quantitation method that is used in the 
control test procedure. Recovery deviations from the theoretical values while 
performing a calibration with a drug substance alone may indicate interferences 
between the analytc and placebo/matrix components. In such a case, the calibration 
should be done with a synthetic mixture of placebo and drug substance standard. Such 
interferences may also be detected by the separate determination of linearity for 
dilutions of the drug substance and for a spiked placebo. Both regression lines can be 
compared statistically or graphically (e.g. by verifying that recovery data are within 
31 
the prediction interval of the drug substance linearity). The accuracy can be 
established in different ways, using statistical analysis (Table 1.4). 
Precision of an analytical procedure expresses the closeness of agreement 
(degree of scatter) between a series of measurements obtained from multiple sampling 
of the same homogeneous sample under the prescribed condition [149], Precision 
should be measured using homogenous authentic samples. However, if it is not 
possible or if it is not practical to obtain a homogeneous sample, it may be measured 
using artificially prepared samples or sample solutions. Precision experiments study 
the effect of random variations on the performance of a method. Precision must be 
assessed in several ways: 
Repeatability, also termed as intra-assay precision, rclers to the precision 
obtained under the same operating conditions over a short interval of time by applying 
the whole analytical procedure to the sample. Repeatability should be assessed using a 
minimum of 6 determinations at 100% of the test concentration or a minimum of 9 
determinations over the range of the procedure (e.g. 3 replicates for each of 3 
concentrations). This will provide an estimate of the random error of the method. 
Intermediate precision refers to within-laboratory variations, preferably 
performing a method over an extended period of time. The extent of investigation will 
depend on the intended use of the procedure. A typical investigation of inlcnnediatc 
precision would study various parameters that might include analysts, days, 
equipment, reagents, columns, etc. It is not required that each effect be studied 
individually so, therefore, experimental design is encouraged. 
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Table 1.4. Quantitative approaches to demonstrate accuracy according to ICH. 
Drug substance Application of the analytical procedure 
to a reference material. 
Comparison of the results with those of 
a second well characterised procedure. 
Drug product Application of the analytical procedure 
to synthetic mixtures of drug product 
components 
Spiking of analyte to drug product. 
Comparison of the results with those of 
a second well characterised procedure. 
Impurities (quantitative) Spiking of the impurity to drug 
substance or product. 
Comparison of the results with those of 
a second well characterised procedure. 
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Reproducibility is an estimate of the variation between different laboratories 
and is usually assessed by performing an inter-laboratory (collaborative) study. A 
study of reproducibility is not required as a part of the marketing authorisation 
dossier. 
Robustness/ruggedness of an analytical method can be defined as "a measure 
of the capacity of analytical procedure to remain unaffected by small, but deliberate 
variations in method parameters and provides an indication of its reliability during 
normal usage" [151]. It can also be described as the ability to reproduce the 
(analytical) method in different laboratories or under different circumstances without 
the occurrence of unexpected differences in the obtained result(s), and a robustness 
test as an experimental set-up to evaluate the robustness of a method. Though these 
two terms have been frequently used as the synonyms [152] but sometimes a mutual 
differentiation have also been made [153], according to which the ruggedness is 
defined as the degree of reproducibility of the test results obtained under a variety of 
normal test conditions, such as different laboratories, different analysts, different 
instruments, different lots of reagents, different elapsed assay times, different assay 
temperature, different days. etc. The ICH guidelines also recommend that one 
consequence of the evaluation of robustness should be that a series of system 
suitability parameters (e.g. resolution tests) is established to ensure that the validity of 
the analytical procedure is maintained whenever used [151]. Deliberate variations in 
the parameters of a procedure will provide an estimate of its reliability in routine use. 
The extent of robustness studies will depend upon the type of method but this 
evaluation should be considered during the development phase. Typical variations 
might include extraction time, flow rate through a testing device, stability of test 
solutions, etc. 
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Statistical treatment of certain validation parameters of common interest in 
analytical methodology 
Linear regression by least square method; Normalisation factor (unweighted linear 
regression: w, = 1, = 1): - ^ 
Means: 
- _ ^ ( X i * ^ ^ * ) - ^ * K ^ ^ ^ ^ l 
X = 
Sum of squares: Q^ Qyy = * O, - y f ) 
Q^ ^^^ - -y)) 
Residual sum of squares (Qyy) and Residual standard deviation (Sy). 
^ V « - 2 
Slope (b), standard deviation of slope (sb) and Relative conjiaence interval of the 
slope (Clt) 
Sb = % 
Intercept (a), standard deviation of intercept (Sa) and Confidence interval of the 
intercept (CLa; upper and lower limits): 
a = y 
1 ^ — + — 
k # 
Standard error (sxo) and Relative standard error of slope (Vxo): 
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Coefficient of correlation (r) • Q^ 
r = 
Residuals and %-Difference • 
Where = experimental j)/-value and>' (x^ = calculated j^value for the given x-value. 
Calculation of concentrations with uncertainties' 
Input of>^values: Calculation of concentral^i CvJ = —^ 
Input of X-values: Calculation of signal y^ = a + b ^ x^ 
Uncertainty and Relative uncertainty: 
+ '—* 
1 n m b'^ ~ m b^ *Q. 
Accuracy 
(1) by comparison and validation procedure: 
- ^ ^ 
Confidence interval {CL(x) upper and lower l imiiCZ(x) = x ± s * ^^  
Variance (s^), Standard deviation (s) and Coefficient of variation (CVor RSD), 
« - 1 
Range [R%], p^ = m^ax ^mn ^ IQQ 
X 
Linearity (overall analysis, unweighted linear regression) 
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Comparison with the slope of the 1st series 
Limits of the equivalence interval: 
UbA 
Cu = m exp - a) - 1 cCi =100 exp - 4 ) ] - l | 
t(P,f) = Student's t- value for level of statistical confidence P and degrees of 
freedom,/= n, + nj~ 4. 
Where bij, sbjj, nj j = slope, standard deviation of the slope, and number of values of 
series 1 and j, respectively. 
The slopes of series 1 and j are equivalent, if ~ - ^ i^^-'u - ^^ ^^  
Accuracy (recovery from linearity): Comparison of the slope with the 
theoretical value of 1. 
Limits of the Equivalence interval: 
-JQ. 
5 = acceptable difference (absolute value). 
t(P,f) = Student's t- value for level of statistical confidence P and degrees of freedom, 
f=n-2. 
Sy, Qxx^ residual standard deviation, sum of squares. 
The slope is equivalent to the theoretical value of 7, if " t3' 1 C C ^ j 1 if"-
Accuracy (100% recovery, comparison to reference): Comparison of ihc mean 
with a nominal value. 
Limits of the equivalence interval: 
C^ =T-x+t{P,n~\) 
-in 
r = nominal value (100% or reference value). 
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5 = Acceptable difference (absolute value). 
t(P,j) =Student's /-value for level of statistical confidence P and degrees of 
freedon -1. 
Where = mean, standard deviation and number of values, respectively. 
Tare equivalent, if - iC ^ ^C^ < 
Accuracy (Comparison to another procedure): Comparison of two means 
/ - \ 
c , = IOC exp[j:(/',«i +«2 - 2 ) s ] - l 
= s/ * 
1 1 + 
2 _ 
+ ^ - 2 
5 % = Acceptable difference (percentage). 
t(P,f) = Student's /-value for level of statistical confidence P and degrees of 
freedom,/=«/+«2 - 2. 
— 2 
Where Jr^j.^j^j ~ rnean, variance, and number of values of series 1 and 2, 
respectively. 
The two means are equivalent, if ~ ^ ^ i ^ ^ u -
Precision (individual series): Comparison of the standard deviation with a 
nominal value. 
=100^ 
Limits for the equivalence interval: 
s 
T\ 
n-\ 
- 1 
s 
f 
- 1 
T = target value for standard deviation 
5 % = Acceptable difference (percentage of the standard deviation). 
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i^' f ) = Chi-squared distribution for level of statistical confidence P or 1 - P and 
degrees of freedom f = n-1. 
2 
x,s mean, variance, and number of values. 
Experimental and target standard deviation are equivalent, if - jy<i < C^ C^- < 
Test for Outliers 
With regard to linearity, an outlier is characterised by a significant deviation 
from the regression curve. The 95% prediction interval can be used as a criterion. This 
interval describes the range around the regression function in which a repeated 
analytical value can be expected in 19 out of 20 cases. If the calculation of the 95% 
prediction interval is performed with all values, a possible outlier might have a 
considerable influence on the calculation (by broadening the interval). The suspected 
value or values can be inactivated manually and a second regression is performed. If 
the deactivated value or values are now outside the 95% prediction interval, they can 
be suspected as being outliers. In the same manner, deviations from a linear response 
performing a linear regression can be detected. However, it must be taken into 
consideration that the prediction interval will be less stringent (broader) as the 
extrapolation increases ("trumpet-shaped"). Most statistical tests and calculations are 
based on the assumption that the experimental values are only influenced by random 
variability (i.e. that they are normally distributed). Data that do not fulfil these 
assumptions (e.g. due to so called "gross errors", weighing, dilution, or by problems 
with the instrument etc.) will affect the results. It is the aim of outlier tests to identify 
such values in order to eliminate them before performing further calculations. 
However, the problem is especially with a small number of data where groupings 
could easily occur avoiding the incorrect rejection of values belonging to the same 
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distribution. Therefore, outlier tests should be applied carefully and only obviously 
deviating values should be eliminated. When an outlier is identified, the absolute 
magnitude of the coefficient of variation (relative standard deviation) must also be 
considered for evaluation. If this parameter (calculated including the suspected 
"outlier") lies in a normally expected range, preferably all values should be retained. 
The question of systematic effects influencing the values (e.g. degradation or 
adsorption of the analyte, shifts in the equipment settings, etc.) is of more importance. 
This can be investigated by applying a trend test in which an unweighted linear 
regression is performed using the values in the order of the input (equidistant spacing 
with respect to the x dimension). The 95% confidence interval of the slope is then 
tested against the slope itself If a slope can not be dctectcd statistically, the 
hypothesis of a systematical trend can be rejected. 
F- and t-tests: 
(i) Mean /-tests: 
2 
F-test: If / l , / 2 ) with si^ > then significant difference of 
" 2 
2^ 
variances exists. F(P, f l , f2) ^ Fisher's F-value for level of statistical confidencc P 
and degrees of freedom fi andy}-
If — * / , j ) significant difference of mean exists. 
n • + fi 
Where 
= 
X — X 
/ 
(ii) Nominal value Mest.-
If — ) t (P, / ) significant difference to the reference exits. 
4 0 
O j -
Where f = rij-l and 
t(P, f ) = Student's /-value for level of statistical confidence P and degrees of freedom 
/ 
and = mean, standard deviation, number of values in validation series. 
CLASSIFICATION OF DRUGS 
All the drugs according to their chemical nature can be divided into organic 
and inorganic compounds. They can be prepared synthetically (from chemicals) or 
can be directly obtained or reconstituted from the natural sources/products. All the 
drugs having medicinal importance can be broadly divided into two classes. 
Chemical classification: Here the drugs are classified according to their 
chemical structure and properties without taking the pharmacological actions under 
consideration. In this class most of the drugs are having at least an organic substrate, 
the further classification is done in the relevant manner. 
Pharmacoloeical classification: In this class the drugs are divided according 
to their action on the organism/organ (viz. heart, brain, lymphatic system, respiratory 
system, endocrine system, central nervous system etc.). Hence these drugs are named 
like cardiovascular, narcotics, soporifics, analgesics, diuretics and anaesthetics etc. 
Further classification of each group is done according to the 
therapeutic/pharmacological specificity with the relevant organ [154], A detailed 
classification of the cardio vascular drugs with respect to their therapeutic importance 
for the treatment of cardiac ailments have been presented in Scheme 1.1. 
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The present thesis deals with the determination of the following drugs: 
Amlodipine besylate (C20H25CIN2O5. CeHeOsS) 
Amlodipine besylate is comparatively a new calcium channel blocker, and is 
chemically defined as 3-ethyl 5-methyl 2-{2-aminoethoxymethyl)^-(2-
chlorophenyl)-! ,4-dihydro-6-methyl pyridine-3,5-dicarboxylate monobenzene 
sulphonate (Structure III). 
H,C. 
H3COOC 
CL H 
CH2OCH2CH2NH2 
COOCH2CH3 
.CgHeOaS 
Structure I 
It also belongs to dihydropyridine group of calcium channel blockers, 
undergoing photodegradation and showing almost similar therapeutic behaviour. 
Labetalol hydrochloride (C19H24N2O3. HCl) 
The British Pharmacopoeia has defined labetalol hydrochloride as all-rac-2-
hydroxy-5-[l-hydroxy-2-(l-methyl-3-phenylpropylamino)ethyl]-benzamide 
hydrochloride. It is an antiadrenergic agent and exhibits combined alpha- and beta-
adrenoceptor blocking property. 
HCl 
Structure II 
4 3 
Angiotensin converting enzyme (ACE) inhibitors inhibit the conversion of 
angiotensin I (inactive) to angiotensin II (active) i.e. they inhibit the production of 
angiotensin II (active form). Lisinopril and captopril belong to this class of drugs. 
Lisinopril (C2iH3iN30s.2H20) 
Lisinopril, according to USP is (S)-l-[N^-(l-carboxy-3-phenylpropyl)-L-lysyl]-L-
proline dihydrate. 
Orally active ACE inhibitor 
COOH 
0 COOH 
Structure III 
Captopril (CgHuNOsS) 
Captropril, according to USP is l-[(2S)-3-mercapto-2-methyl]-l-oxopropyl]-l-[(2S)-
3-mcrcapto-2-methyl propionyl]-L-proline. 
H 
HSCH 
CH3 
2 C=0 
COOH 
H 
Structure IV 
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spectrophtometric determination of milodipine 
hesplate in pharmaceuticdformulations 
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Introduction 
Amlodipine besylate (I) is a dihydropyridine type long acting calcium channel 
blocker with slow onset of vasodialatory action [1 - 2]. The use of this important life 
saving drug is approved for the treatment of variant and stable angina and 
hypertension, too [3 - 4], As an additional property, amlodipine inhibits vascular 
smooth muscle cell growth through interactions with targets other than L - type 
calcium channels [5] and is more selective for arterial vascular smooth muscle than 
cardiac tissues. It has been investigated that amlodipine exhibits ameliorating effects 
on plasma and myocardial catecholamines with a significant reduction of calcium 
deposition and may be useful in dilated cardiomyopathy [ 6 - 7 ] . 
Various analytical methods have been reported for the assay of amlodipine 
besylate in pure form as well as in pharmaceutical formulations. They include high 
performance liquid chromatography [8 - 13], reversed phase high performance liquid 
chromatography [4, 14 - 16], high performance thin layer chromatography [17-20] , 
gas chromatography [21], gas chromatography-mass spectrometry [22], liquid 
chromatography with tandem mass spectrometry [23] and fluorimetry [24]. 
As far as sensitive and economical methods of assay are concerned, few 
spectrophotometric methods have been reported for the quantification of amlodipine 
besylate based on extractable ion pair complexes [25-29], oxidative coupling with 3-
methyl 2-benzothiazolinone hydrazone hydrochloride [30], reactions with sodium 
hydroxide, ninhydrin and ascorbic acid in N, N'-dimethylformamide medium [31-
33], derivative spectroscopy [34-35], simultaneous multicomponent mode of analysis 
and difference spectrophotometry [36-38], charge transfer complexation [33, 39-41], 
and reduction of Fe (III) and subsequent interaction of Fe (II) with ferricyanide [42], 
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The inorganic oxidants such as Fe(III) [43], vanadate [44], molybdate [45] and 
permanganate [46] have been used to determine pharmaceuticals in dosage forms. 
In this chapter, three spectrophotometric methods for the determination of 
amlodipine besylate have been proposed. The first two methods (method A and B) are 
based on the reduction of Fe(III) by amlodipine besylate and consequently Fe(II) 
produced is estimated by chelation with 1,10-phenanthroline (method A) or 2,2'-
bipyridyl (method B). In the third procedure (method C), molybdate is reduced to 
molybdenum blue which is determined at 825 nm. All the three methods were found 
to be more sensitive in comparison to the existing spectrophotometric methods. 
Experimental 
Instruments 
Spectronic 20D^ spectrophotometer (Milton Roy, U.S.A.) and pH-meter 
model Ll-IOT (Elico, India) were used to measure the absorbance and pH, 
respectively. A temperature controlled water bath (NSW, New Delhi) was used to 
control the temperature. 
Reagents and Materials 
(i) 0.1% amlodipine besylate stock solution was prepared by dissolving 100 mg 
of pure drug (M/s. Wockhardt Ltd., India) in minimum volume of glacial 
acetic acid for methods A and B. and in minimum volume of methanol for 
method C. The whole contents were diluted to 100 mL with doubly distilled 
water. Further dilutions were made with water according to the need. 
(ii) 0.25% ferric ammonium sulphate solution was prepared in 0.08 M sulphuric 
acid. 
(iii) 2.5xl0-^M ammonium heptamolybdate tetrahydrate solution was prepared in 
4 M sulphuric acid. 
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(iv) 0.6% 1,10-phenanthroline and 1.0% 2,2'-bipyridyl solutions were prepared in 
ethanol. 
(v) Buffer solutions: sodium acetate-acetic acid buffer of pH 4.6 was prepared by 
mixing equal volumes of 0.2 M sodium acetate and acetic acid. The disodium 
hydrogen phosphate-citric acid buffer of varying pH values were prepared by 
mixing appropriate volume of 0.2 M disodium hydrogen phosphate and 0.1 M 
citric acid. The pH was adjusted with the aid of pH-meter. All other chemicals 
used were of analytical reagent grade. 
Recommended procedures 
Method A 
Aliquots corresponding to 2 - 10 f^ g mL"' of amlodipine besylate were 
pipetted into a series of boiling tubes. Then 2.0 mL of 0.25% ferric ammonium 
sulphate, 2.5 mL of sodium acetate-acetic acid buffer of pH 4.6 and 0.5 mL of 0.6% 
1,10-phenanthroline were added successively in each tube. The contents were mixed 
well and placed in a water bath for 20 minutes to develop the colour. After heating, 
the tubes were cooled to room temperature and the contents were finally transferred to 
10 mL volumetric flasks and completed to volume with doubly distilled water. 
Method B 
Into a series of boiling tubes, amlodipine besylate solution in the concentration 
range of 4 - 14 ^g mL"' were transferred, followed by 2.0 mL of 0.25% ferric 
ammonium sulphate solution. The contents of each tube were heated on a water bath 
for 20 minutes. 2.5 mL of sodium acetate-acetic acid buffer of pH 4.6 and 1.0 mL of 
1.0% 2,2'-bipyridyl were added in each tube after taking them out from the water 
bath. The contents were transferred to 10 mL volumetric flasks and made upto the 
mark with doubly distilled water. 
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Method C 
Aliqouts of amlodipine besylate solution corresponding to 15 - 59 i^g mL"' 
were transferred into a series of boiling tubes. To each tube 2.5 mL of 2.5 xlO"^ M 
ammonium heptamolybdate tetrahydrate and 5 mL of disodium hydrogen phosphate-
citric acid buffer solution of pH 4.0 were added and the contents were heated on a 
water bath for 25 minutes. It was transferred to 10 mL volumetric flasks after cooling 
and diluted to the mark with doubly distilled water. 
The absorbances were recorded against their corresponding reagent blanks 
prepared simultaneously at 500, 515 and 825 nm for methods A, B and C, 
respectively. 
Analysis of pharmaceutical formulations 
10 tablets of different brands available in the local market equivalent to 100 
mg of amlodipine besylate were crushed and finely grounded to powder and extracted 
into sufficient volume of chloroform with shaking. It was filtered through sodium 
sulphate kept on a glass-wool bed. The filtrate was evaporated to dryness. Dry residue 
was dissolved with glacial acetic acid for methods A and B, and in methanol for 
method C. and made upto the mark with doubly distilled water. The assay was 
completed following the recommended procedures. The amount of drug was 
calculated cither from the calibration graphs or the regression equations. 
Results and discussion 
The amlodipine besylate contains amino group and hence able to reduce Fe 
(111) to Fe (II) and Mo (VI) to Mo (V). The reduced Fe (II) reacts with 1, 10 
phcnathrolinc (method A) or 2, 2'-bipyridyl (method B) to form red coloured 
complexes which absorbed maximally at 500 nm and 515 rmi, respectively. In method 
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C, the intense blue colour owing to the fomiation of molybdenum blue having an 
absorption maximum at 825 nm is utilized for quantification of the cited drug. 
Optimization of reaction conditions 
The optimum conditions for the formation of maximum colour were studied 
and maintained throughout the experiment. In order to obtain the highest and most 
stable absorbance the effect of the reaction time on the absorbance of the product was 
studied. The reactions were performed on a water bath at 100 ±1 °C for the periods 
ranging from 5 - 3 0 minutes. Maximum and constant absorbance was obtained after 
18 minutes for the methods A and B whereas 22 minutes for the method C. The 
results are shown in Fig. 2.1 - 2.3 
The effects of other variables (methods A and B) such as concentration of 
Fe(III) and 1,10-phenanthroline or 2,2'- bipyridyl have been investigated to develop 
maximum colour by adding to 10 |ig mL~' amlodipine besylate. The results are shown 
in Figs. 2.4 - 2.7. Therefore, 2.0 mL of 0.25% Fe(III) and 0.5 mL of 0.6% 1,10-
phenanthroline or 1.0 mL of 1% 2,2'-bipyridyl were used throughout the experiment. 
The effect of reagent concentration for method C was studied by adding 
different volumes of 2.5 xlO~^ M ammonium heptamolybdate tetrahydratc solution to 
a constant amount of amlodipine besylate (250 ng). It was observed (I'ig. 2.8) that the 
maximum colour intensity was obtained with 1.1 mL of the reagent, after which 
further increase in volume resulted in no change in absorbance. Thus, 2 mL of the 
reagent was sufficient to reach with the maximum drug concentration in the Beer's 
range. 
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The second variable in this method was the pH of the medium. An 
investigation of the pH of the medium showed that the pH in the range of 3.0 - 5.0 
was sufficient to develop the colour. Therefore, disodium hydrogen phosphate-citric 
acid buffer of pH 4.0 was used throughout the experiment. 
Analytical data 
Under the optimized experimental conditions, the optical characteristics and 
the statistical parameters for the proposed methods are summarized in table - 2.1. An 
investigation of the intercept, standard deviation of the intercept and slope [47], 
variance [48], standard error of estimate, correlation coefficient and linearity [49] 
suggest ihe excellent linearity of the calibration graph of method A followed by 
method B and C, respectively (Fig. 2.9, 2.10 and 2.11). The comparative study of the 
molar absorptivity. Sandell's sensitivity [50], detection limit [48] and slope indicated 
good sensitivity of the proposed methods which again follow the order A > B > C. A 
comparison of all these methods with the existing spectrophotometric methods 
(lable - 2.2) shows that the proposed methods are more sensitive with lower RSD. 
However, the linear dynamic ranges of the developed methods are narrow. 
The uncertainly (AC/C)% in the determination of amlodipine besylate 
ihroughout the range of calibration of each method was calculated at 95% and 99% 
confidcncc levels [51] and plotted against the concentrations (Fig. 2.12, 2.13 2.14). 
ll is apparent from the figures that the uncertainties are higher at very low 
concentrations. 'ITiercforc, it is suggested that the methods be operated above 4 and 6 
J 
i^g mL"' (method A), 6 and 8 }ig mL"^  (method B) and 25 and 35 p.g mL"' (method C) 
concentrations at 95% and 99% confidencc levels, respectively, to avoid higher 
uncertainty on the results of the analyses. 
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Table - 2.1: Spectrophotometric characteristics and statistical data of the regression 
equations. 
Parameters Methods 
A B C 
Beer's range (^g mL"') 2 - 1 0 4 - 1 4 15 -59 
Absorption maxima (Amax. - nm) 500 515 825 
Molar absorptivity 
(L moF^ cm~ )^ 
2.9 xlO'^ 2.7 X lO"* 1.8 x lO'' 
Sandell's sensitivity 
{[ig cm^per 0.001 AU) 
1.95x10"^ 2.10 x 10"^ 3.15 x 10"^  
Limit of detection (^g mL"') 0.08 0.12 0.35 
Limit of quantitation (ng mL~') 0.83 1.2 3.5 
Regression data: 
Intercept (a) 0.8x10"^ 4.9x10"^ 2.2x10'^ • 
S.D. of intercept (Sa) 2.2 X 10"^  3.2x10'^ 1.1 x 10'^ 
Slope (b) 5.1x10"^ 4.6 X 10"^ 3.1 x 10'^ 
S.D. of slope (Sa) 4.7x10'^ 6.5x10"^ 2.2 X 10'^  
tS/ 3 .3x10^ 3.4 x lO"* 2.6 X 10-^  
ts-/ 7 .0x10^ 6.8 x 10^ 5.2 X 10"' 
Correlation coefficient (r) 0.9998 0.9996 0.9995 
Variance (So )^ 4.3x10"^' 8.2x10"^ 6.6 X 10"^  
Standard error of estimate (Se) - 2.1 x 10"^ 2.8x10"^ 9.9 X 10"' 
Linearity (5irei)% 0.65 0.73 0.83 
in reference [51]. 
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Tabic - 2.2: Comparison of the proposed methods with the existing 
spectrophotometric methods for the determination of amiodipine besylate. 
Reagents ^max. 
(nm) 
Beer's 
range 
(^ K inL"*) 
Molar 
absorptivity 
(L mor^ cm"^) 
%RSD References 
Eriochrome black - T^ 495.0 5 - 5 0 6.54x10' 0.88 25 
Indigocarmine ^  590.0 2 5 - 1 5 0 1.96x10^ 0.87 25 
Bromocresol green ^ 409.0 0 - 8 0 - — 26 
Bromophenol blue ® 409.0 0 - 8 0 - - 26 
Methylene blue ® , 668.2 0 - 8 0 - - 26 
Rhodizonic acid ® 450.0 100-1500 - — 27 . 
MBTI-I'' 630.0 5 - 4 0 9.07x10^ 0.87 30 
Sodium hydroxide 456.0 20 -100 — 1.90 31 
Ninhydrin 595.0 10 -60 6.52x10^ 0.66 32 
DDQ' 580.0 1 - 1 2 5 0.6x10^ 0.32-1.53 33 
Ascorbic acid 530.0 10-140 0.32 X 1 0 ^ 0.36-1.05 33 
p-chloranilic acid 540.0 100-600 0.91x10^ 0.52 38 
Fc(l 11)-Ferricyanide 760.0 5-15 1.76 X 10^ 0.35-4.90 42 
r e ( I I I ) - P T l / 500.0 2 - 1 0 2.9 x 10^  0 .39-0.52 This work 
F e ( m ) - B P L ' S15.0 4 - U 2.7 X 0.63-0 .78 This woik 
Ammonium 
hcplamolybdate 
825.0 1 5 - 5 9 1.8 X 1 0 ^ 0,30-0 .35 This work 
'^ ^Bxiractive methods; ,3 - methyl 2 - benzothiazolinone hydrazone hydrochloric 
^ ,^2,3- dichloro 5,6- dicyano 1,4- bcnzoquinone; 1,10-phenanthroline; 2,2 '-
' bipyridyl. 
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The precision studies of the proposed methods were done by carrying out ten 
independent determinations at two concentration levels (Table 2.3). The relative 
standard deviations (RSD) were found in the range of 0.39 - 0.52, 0.63 - 0.78 and 
0.30 - 0.35% for the methods A, B and C, respectively. The results are presented in 
table-2.3. 
For additional confirmation of the accuracy and precision of the proposed 
methods, standard addition method was performed by adding a known amount of pure 
drug to the preanalyzed dosage forms. The results are summarized in table 2.4 and 
considered to be very satisfactory. 
Table 2.5 shows the results obtained for the determination of amlodipine 
besylate in pharmaceutical formulations by the proposed methods and the reference 
method [30]. The t - and F— values calculated from the experimental data were found 
to be smaller than the theoretical ones at 95% confidence level [52]. Thus, there were 
no significant differences between the two sets of the results. 
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Tabic - 2.3: Evaluation of the accuracy and precision of the proposed procedures. 
Proposed 
methods 
Amount (^g mL 
Taken Found ±SD' 
%RSD ^ SAF," Confidence 
limit 
A 5 4.97 ±0.03 0.52 0.010 0.0174 
10 10.01 ±0.04 0.39 0,013 0.0232 
B 8 8.06 ±0.06 0.78 0.019 0.0348 
12 12.05 ±0.08 0.63 0.025 0.0464 
C 25 25.01 ±0.09 0.35 0.029 0.0522 
40 39.88 ±0.30 0.30 0.038 0.0696 
Mean ± S.D. for ten determinations; standard analytical error; confidence limit 
at 95% confidence level and 9 degrees of freedom with t-values as in reference [51]. 
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c h a p t e r 3 
^ d i d a t i m ofoptimvzed spectrophotmetric 
method f o r the sebctive determination oj 
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Introduction 
Labetalol hydrochlorid(- (I) is an important non-cardioselective antiadrenergic 
agent with some intrinsic synip^thomimetic and membrane stabilizing activity. As 
chemically defined in pharmacopoeias, it is 2-hydroxy-5-[l-hydroxy-2-(l-methyl-3-
phenylpropyIamino)ethyl] benzannde "hydrochloride 11,2]. Lal^etalol is used "in the 
management of hypertension and to induce hypotension during surgery as it decreases 
blood pressure more rapidly than other beta-blockers. Beside these important 
pharmacological activities, labetalol administration exhibits a number of 
complications due to both alpha- and beta-blocking properties. Labetalol therapy 
exhibit hepatotoxicity and renal failure too, due to overdosage. 
It is metabo\ized predot^ ii^ ^T^^W ^^ ^ ^ the metabo\Ues being excieled 
the urine, faeces and breast milk with small amounts of unchanged labetalol. The two 
reported metabolites of labetalol are 0-sulfate (major, II) and 0-glucuronide (minor, 
III) products as a result of adopting sulfation and glucuronidation pathways of 
metabolism, respectively (Scheme 3.1) [3]. In both the cases, phenolic group of the 
drug is denatured. 
With the advent of International Confcrcncc on Ilarmonization (ICM) 
guidelines, the requirement of stability indicating assay method (SIAM) has become 
more clearly mandated. The guidelines explicitly require conduct of forccd 
decomposition studies under a variety of conditions [4]. In other guidelines {5,6). ICII 
defines certain parameters and methodology for the validation of analytical 
procedures that include specificity, accuracy, precision, linearity, range, dciccllon 
limit (needed in some cases) and quantitation limit. 
8 7 
NH2 + 
H 
Photo/oxidative degradation 
H ,CH3 
CONH2 
lucuronidation 
OH 
OH 
COO" 
III 
Scheme 3.1 
A number of methods for the determination of labetalol hydrochloride have 
been reported in the literature which includes spectrophotometry [7,8,9,10,11,12], 
NMR spectroscopy [13], TLC [14,15,16], HPLC [17,18,19,20], LC-MS [21,22], GC 
[23,24], micellar liquid chromatography [25], capillary electrophoresis [26,27], 
capillary liquid chromatography [28], polarography [29] and spectrofluorimetry [30], 
in which few of them are stability-indicating. Most of them are either too expensive or-
poorly selective and insensitive, and are not easily manageable in the laboratories of 
the developing countries. Fewer studies have been done in detail for the selectivity of 
the proposed procedures and to evaluate its analj^ical applicability. However, Belal 
and coworkers have exploited the phenolic group of labetalol for its assay in 
pharmaceutical formulations within a narrow range of determination, and also in 
biological samples after an extractive pretreatment [7,30]. These methods have 
adequate sensitivity to assay lower concentrations of the drug and hence use of these 
methods is justified for the complex sample matrix as in the case of biological 
samples. The sample matrix is usually less complex and analyte concentrations are 
high in case of pharmaceutical analysis. Further, it is better for biological samples if a 
direct procedure can be adopted rather than to follow an extractive procedure which 
may cause the loss of the analyte during the process of extraction due to insufficient 
solubility of the analyte in the exlractant and other handling mistakes. 
This chapt&r describes a method for the determination of labetalol in pure form 
and pharmaceutical forrnulations based on the reaction with sodium nitroprusside and 
hydroxylamine hydrochloride in a bufler of pH 12. During the development of the 
procedure, the rnethod has been carefully optimized to enhance the sensitivity as well 
as selectivity of the determination of labetalol and robustness of the assay. Careful 
approaches have been achieved for the validation of the method by incorporating 
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rigorous statistical analyses wherever needed, and thus preventing any misleading 
interpretation from the raw data obtained during the experimental works. A detailed 
investigation on the selectivity of the method has been done to evaluate the 
applicability of the procedure in the presence of various types of interferents. 
Experimental 
Instruments 
Spectronic 20D^ and 21D (Milton Roy, USA) have been used for recording 
the spectra and to perform absorbance measurements. Model Ll-IOT pH-meter 
(Elico, India) and pyrex glass photoreactor equipped with magnetic stirrer and 125 W 
medium pressure mercury lamp (Philips), have been used for pH measurement and 
photodegradation, respectively. 
Materials and reagents 
All the chemicals used were of analytical reagent grade or equivalent. Doubly 
distilled water was used throughout the experimental work. 
0.1% aqueous solution of labetalol was prepared by dissolving 100 mg of 
labetalol hydrochloride (Sigma, USA) in a 100-mL volumetric flask and further 
diluted according to the need. A 0.1% solution of labetalol hydrochloride was also 
prepared in a buffer solution of pH 9 for photodecomposition. A buffer solution of pH 
12 was prepared by the method of Kang et. al [31]. Aqueous solutions of sodium 
nitroprusside (SNP; S.D. Fine Chemicals, India) 1%, hydroxylamine hydrochloride 
/ 
(HH; Ottokemi, India) 1% and 0.2% potassium permanganate (ICMn04; B.D.H., 
India) solutions were also prepared. 
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Human urine and blood samples were collected from healthy volunteers and 
bovine serum albumin powder was purchased from S.R.L. India, to study the 
interferences in biological matrices. 
Preparation of degradation products 
Acidic degradation products 
Into a 50-mL round bottom flask, 10 mL aqueous solution containing 25 mg 
labetalol hydrochloride was transferred followed by 12 mL of sulfuric acid (98%; E. 
Merck, India). The whole content was refluxed for 75 minute during which a purple 
coloured product finally turning to deep brown was obtained. It was cooled and 
maintained to pH 7.0 ±0.05 with the aid of pH-meter by adding sodium hydroxide 
solution. The whole content was left for 6 hours. Finally, it was filtered through glass 
wool bed into a 100-mL volumetric flask and maintained to the volume with its 
washings. 
Photodegradation products 
Photodecomposition of labetalol was done by the method of Andrisano et. al 
[32]. 25 mL of the solution was taken out from the photoreactor, neutralized with 
dilute sulfuric acid and collected in a 100-mL volumetric flask. The whole content 
was made upto the mark with its washings. 
Oxidative degradation products 
Into a 25 mL aliquot of 0.1% aqueous solution of labetalol hydrochloride 50. 
mL of 0.2% KMn04 solution was added, mixed well and left at room temperature for 
90 minutes. The excess of KMn04 was decolourized with saturated solution of oxalic 
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acid, followed by neutralization with sodium hydroxide. Finally, the whole content 
was transferred into a 100-mL volumetric flask and made upto the mark with water. 
Optimization of reaction variables 
The reaction variables have been optimized with repeated investigations, 
which are discussed below: 
Effect of time 
2.5 mL aliquots of 0.05% labetalol hydrochloride solution were transferred 
into a series of 25-mL volumetric flasks, followed by 1.75 mL of SNP and 5 mL of 
pH 12 buffer solutions. They were mixed well and left for 2 minutes. Then 2,35 mL 
of HH solution was added in each flask and shaken vigorously for a moment. They 
were kept aside for varying time intervals with intermittent disturbances, diluted upto 
the mark with distilled water and read against their corresponding reagent blanks at 
695 nm. 
Similarly the effects of other reaction variables like volumes of SNP (1%), 
buffer (pH 12) and HH (1%) solutions have been optimized at an optimum time of 15 
minutes, 1.75 mL of SNP, 5 mL of buffer and 2.35 mL of HH, omitting successively 
variable under investigation. 
Recommended procedure 
Aliquots of labetalol hydrochloride (2.5 mL) in ihc concentration range or2 -
51 |ig mL"^ were carefully pipetted into a series of 25-mL volumetric flasks. To each 
flask, 1.75 mL of SNP and 5 mL of buffer (pH 12) solutions, were added. It was 
mixed gently and left for 2 minutes. Then 2.35 mL of HH solution was pipetted into 
each flask, mixed well by vigorous shaking for a moment and left at room 
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temperature for 15 minutes. The contents were intermittently disturbed. Finally, after 
15 minutes, the whole content was made upto the mark with distilled water^and read 
against the reagent blank prepafed simultaneously at 695 nm. The amount of the drug 
was calculated from the calibration graph of absorbance v .^ concentration or 
alternatively by the regression equation. 
Analysis of pharmaceuticalfofftulations 
Due to the unavailability of the commercial dosage forms in the local market 
¥ 
at the time of this study, synthetic samples of different known concentrations (A, B 
and C) have been prepared in this laboratory. They were treated as the dosage forms 
and analyzed. The laboratory prepared dosage forms were further finely grounded 
separately and dissolved in w^ter. It was shaken well and filtered through tightly 
packed glass wool bed into lOO-mL volumetric flasks. The whole content was made 
upto the mark with washings aJid further diluted according to the need with water. It 
was analyzed following the reconunended procedure. 
Method validation 
Linearity 
This validation characteristic includes the linearity of detector response 
(samples obtained by dilution of a single analyte preparation) and the linearity of the 
analytical procedure (individu^ly prepared samples at varying concentrations). A 
minimum of 5 concentrations, preferably evenly spaced, is recommended for linearity 
evaluation [6]. In this study, eight concentrations were choosen, ranging between 2 -
51 ^g mL"'. Sixteen- samples were prepared to perform the duplicate runs at each 
point. The repeated runs were the genuine repeats and not just the repetitions at the 
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same reading. This approach provides information on the variation in the absorbance 
between samples of the same concentration. All of them were included in the 
calculation of the regression coefficients and fiirther statistical analyses. 
Precision 
Repeatability and intermediate precision experiments were performed at three 
concentration levels, i.e. 5, 25 and 45 jag mL"\ The data for each concentration levels 
were evaluated by one-way analysis of variance (ANOVA). One analyst performed 
the intra day precision with six repetitions at each of the three concentration levels 
using the same solutions. The inter day precision was performed by another analyst 
using freshly prepared solutions with two repetitions and another instrument at each 
of ihe three concentration levels on altemate days during a total period of eight days. 
Thus a total fourteen observations at each concentration were taken together for the 
evaluation of the repeatability and intermediate precision. 
Range 
The calibration range was established through consideration of the practical 
range necessary according to the use of the labetalol hydrochloride in pharmaceutical 
formulations as well as its presence in the biological samples. 
Dctcction and quantitation limits 
According to ICH recommendations, the approach based on the standard 
deviation of the response and the slope was used for determining the detection limit 
[6]. The quantitation limit was also calculated. The calculated values with the 
aforementioned approach were further compared with those values calculated with 
certain alternative approaches to decide their closeness of agreement. 
9 4 
Specificity/selectivity 
In order to check the selectivity of the developed procedure, the interference 
of different types of possible interferents have been studied in known concentrations 
of the drug. The results obtained were compared with the standard values to know the 
percent recovery. 
Accuracy 
Accuracy of the method was assessed by the recovery studies using standard 
addition method and by the comparative studies with a reference method. 
Results and Discussion 
SNP is a compound of analytical importance, which is used as a sensitive and 
economical reagent for the selective analysis of different organic functional groups 
and pharmaceutical compound [33,34]. Nagaraj and coworkers have reported that 
phenols undergo reaction with SNP and HH to produce a green - blue colour in the 
pH range 10.26 - 11.46 [35]. The drawback of that procedure was the proper choice 
of buffer solution, as a result of which no reaction has been observed with certain 
important phenols like o- and p-cresol. Kang ei. al have modified the same procedure 
with the development of a buffer which resulted in better sensitivity and wider range 
of applicability for the determination of phenol and other phenolic compounds [31]. 
In the present study, the authors came to observe that under similar conditions 
and procedure as reported earlier which is based on the use of comparatively dilute 
solutions of SNP and HH, labetalol does not produce any green - blue colour. 
However, it was found to undergo similar reaction producing a green - blue colour 
X^ ax 695 nm, (Fig. 3.1) with certain specific modifications. Thus it has been decided 
0.75 n 
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0) 0.45 -o c 
CO 
XI W-. O 
CO 
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— 775 825 
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Fig, 3.1. Absorption spectra of green - blue coloured nitroso derivative of 
labetalol (•) and its reagent blank (o). 
9 6 
to optimize the conditions for the selective detennination of labetalol. It can be 
concluded from this study, and the work of Nagaraj and BCang that in case of certain 
compounds having most of the positions on the ring bearing phenolic group occupied, 
more and more strong conditions specially with respect to HH concentration, are 
required. In case of simple phenolic compounds, a steep decrease in the response can 
be observed even with a slight increase in the concentration of dilute HH. On the basis 
of the literature background a tentative reaction mechanism has been proposed and 
given in scheme 3.2, 
During the process of optimization of the proposed procedure, il was found 
that a temperature of 26 - 40 ±1 °C has no effect on the reaction. Any deviation from 
this range causes incompleteness of the reaction. So all the studies were performed in 
the same temperature range. Different types of buffers like Britton and Wellford, 
Naegeli and Tyabji, Kolthoff and that of the Kang et. al have been tried. The later 
one was found to be most suitable. In other buffer systems either the reaction does not 
proceed or proceeds at such a slower rate that the feasibility of the reaction does not 
seem to be suitable. The concentrations of SNP and HH solutions in the earlier 
reported range [31], (0.3% and 0.28%, respectively; 1 mL of each diluted in 50-mL 
volumetric flask), were also tried; the reaction does not happen. The results of the 
optimization of variables are sunomarized in Figs. 3.2, 3.3, 3.4 & 3.5 from which it 
can been concluded that 15 minutes of reaction time, 1.75 mL of SNP, 5 mL of buffer 
and 2.35 mL of HH solutions can be used as the optimum values. 
Analytical data and statistical analysis 
Under the optimized experimental conditions, the calibration data obtained 
describes a linear relationship between the concentration of labetalol (pg mL~ )^ and 
o 
CM 
X 
+ 
CM 
X 
' X o 
+ (N| 
X 2 X o o o 
ffi o o CN 
X (N < 
+ 
VO + 
o 
£ (N 
Z 
v o CO 
+ + 
CM 
X 2 o o 'o 
CM 
X 
o o 
fs I—J 
0 
1 
(N 
<N 
+ 
1—1 
o 
i-H 
I 
(S (D 
[X, 
' I 
(N 
ri 
tn 
<u 
B o ja u C/I 
0.70 
0.65 ^ 
9 8 
8 c ra JD 
o in 
€ 
0 . 6 0 
0.55 A 
0.50 -J 
0.45 
10 15 
Hme (in minute) 
"T" 
20 25 
Fig. 3.2. Effccl of time on the progress of reaction. 
0.70 
0.65-
9 9 
8 
I 0.60 
o (n 
0.55-
0.50 
1.0 1.5 2.0 
Volume of sodium nitroprusside (mL) 
2.5 
Fig. 3.3. Effect of volume of sodium nitroprusside solution (1 %) on the 
• formation of nitroso derivative of labetalol hydrochloride. 
0.70-1 
0 .65-
1 0 0 
8 c OJ 
•Q 0.60 
o V) 
0.55-
0.50 
4.0 
— I 1 1 1 J — 
4.5 5.0 5.5 
Volume of buffer solution (mL) 
6.0 
Fig. 3.4. Effect of volume of buffer solution (pH 12) on the formation of 
nitroso derivative of labetalol hydrochloride. 
101 
0.70-
0.67-
8 
0.64-
0.61-
0.58-
0.55 
Volume of hydroxylannine hydrochloride solution (mL) 
Fig. 3.5. Effect of volume of hydroxylamine hydrochloride solution (1%) on 
the formation of nitroso derivative of labetalol hydrochloride. 
1 0 2 
the absorbance with excellent fitting results (Fig. 3.6). According to these results, the 
regression equation follows a linear model as Absorbance = 1.28 xlO^ + 131 xlO~^ x 
Concentration. The /-statistic of slope, correlation coefficient (rj and the residual 
standard error of estimate were 240.774, 0.9998 and 0.00274, respectively. Generally, 
the value of r is high in instrumental analyses, so it is better to see that whether the r 
is significant or not. This was simply done by calculating the r-value for r using the 
following formula [36], which was found to be greater than the tabulated value 
(187.055) indicating a significant r. 
The r^ statistic indicates that the model as fitted explains 99.96% of the 
variability in the absorbance. Moreover, the correlation coefficient (r) has been often 
used as a crude parameter for linearity on the ground that a linear calibration function 
usually gives a high correlation coefficient and thus misleading in the context of 
testing for linearity. So, in fact, a numerical value of r cannot be interpreted in terms 
of degree of deviation from linearity. Therefore, to assure the goodness of fit in the 
calibration graph, lack of fit test was performed [37]. The results obtained are 
summarized in Table 3.1. It is evident from the data obtained that the F-value found 
by the ratio of the mean of squares of the lack of fit value to that of the pure error is 
less than the tabulated values; thus indicating that the goodness of fit is maintained in 
all the sets of the calibration data. The P-value of the lack of fit test is greater than 
0.05, therefore the lack of fit is not significant. The F-value for the regression is very 
high while the P-value is 0.000, thus there is statistically significant relationship 
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Fig. 3.6. A typical calibration curve for absorbance vs. concentration of labetalol 
showing the line of best fit (solid), confidence band {dotted) and the 
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between the absorbance and concentration of labetalol. It is evident from the table that 
the pure experimental error is comparably large for all factor combinations, indicating 
that the data are homoscedastic but not heteroscedastic [37]; so an unweighted linear 
regression is suitable. It does not require performing a weighted linear regression. Fig. 
3.6 is the linearity plot relating to absorbance and concentration showing the best fit 
line and 95% confidence band for the true mean value of absorbance; visual 
observation of this plot shows that there are no outliers with respect to the model. The 
plot of absorbance vs. predicted values (Fig. 3.7) shows the linearity of the assay. 
Fig. 3.8 shows the dependence of residual plot on the predicted jj^-values. It can be 
observed that the residual plot has no structure at all, thus fulfilling the ideal condition 
by ignoring the possibility of any trend in the data. The Cook's distance for the 
recognition of influential observations is shown in (Fig. 3.9). The four most 
influential values in the Cook's plot can be identified in the residual plot. 
The results of the repeatability and intermediate precision performed at three 
different concentration levels are summarized in table 3.2. The univariate ANOVA 
[36] of the data at each concentration level yields F-value less than that of the critical 
value while P-values of the F-tests are always greater than 0.05; thus confirming that 
ihcre is no statistically significant difference between the mean absorbance from one 
analyst to another, one instrument to another, one solution to another prepared on the 
successive days and finally from one level of day to another at the 95% confidence 
level. 
According to the approach established in the validation section, the calibration 
range was 2 - 5 1 |ig mL"'. The corresponding detection and quantitation limits 
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expressed in concentration units were 0.538 and 1.633 fig mL"'. The alternative 
methods for the calculation of the DL and QL, i.e. from the prediction interval and 
from relative uncertainty, yield the values 0.781 and 0,777, and 1.170 and 1.172 t^g 
mL"' for DL and QL, respectively; thus the values are in good agreement with our 
established approach. 
The accuracy of liie proposed procedure was confirmed by applying 1iie 
standard additon method for the recovery .studies on the three different types of the 
synthetic samples prepared in the laboratory. The results are shown in Fig. 3.10 and 
summ^zed in table 3.3. The standard deviation was calculated from the equation 
given below [36]. The recoveries, S.D. and %RSDs are satisfactory. 
, I U _ 
For the validation by comparison to another reported reference method [9], the 
point as well as interval hypothesis approaches were adopted [38] beside the paired 
two samples for means and independent significance tests. The results (Table 3.4 and 
3.5) show that there is no significant difference between the methods compared and 
the results are within the limit of the validation requirements, i.e. ±2% at 95% 
confidcnce level. 
To assess the selectivit)' of the method, various types of interferents generally 
expected in the Sample matrix and likely to interfere have been added in the pure drug 
and the recoveries were estimated. Table 3.6 shows that the method is highly selective 
for the determination of the drug in the presence of the common excepients in the 
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Table 3.6 Tolerance limit for different type of interferents. 
Excepinets 
Glucose 
Fructose 
Lactose 
Maltose 
Sucrose 
Starch 
Degradation products 
Acidic degradation products 
Photodecomposition products 
Oxidative degradation products 
Biological matrices 
Human, urine 
Bovine serum albumin 
Dcprolinized human plasma 
Tolerance limit (mg) per 50 jig mL 
18 
18 
15 
23 
27 
12 
Tolerance 
90% 
3% 
2% 
Tolerance 
2.25 m L ( 5 | i g m L - y 
11.25 m g ( 5 ^ g m L - y 
0.35 mL (40 ^g mL"*)'' 
-1 
Values in the parentheses are the lowest amount of labetalol to be determined. 
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pharmaceutical formulations and its acidic degradation products, and similar 
possibilities are also clearly expected with the metabolites of this drug as their 
structure reveals (II and III). However, the method was found to be less selective in 
the presence of the oxidative and photo-degradation products since they are tolerable 
upto 3%. Other phenolic compoimds may be one of the starting material or an 
intermediate in the synthesis of the drug, so the interference of the simplest 
compound, i.e. phenol was also studied, and found to be tolearable upto 5%. As far as 
biological samples are concerned, we believe that they may be serious interferents and 
the extent of their interference depends on their actual quantity taken during the work 
of direct analysis. So it was decided to evaluate their maximum tolcranco limit rather 
than only evaluating the recovery from the biological samples. The results obtained 
are presented in table 3.6. It is apparent "from the table that the cited drug can be 
successfully determined m the human urine and serum albumin. 
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Introduction 
Lisinopril, 1 -[N-[(S)-l-carboxy-3-phenyIpropyI]-L-lysyl]-L-proline dihydrate, 
is an angiotensin converting enzyme (ACE) inhibitor. It is used in the treatment of 
hypertension and heart failure. The increasing use of this recently introduced drug, 
which is highly susceptable "to the acidic degradation, needs simple, sensitive and 
selective method for the routine analysis in pharmaceutical formulations. 
Certain successful attempts have been made for the determination of lisinopril 
using different analytical techniques. The generally used analytical techniques are 
liquid chromatography [1], HPTLC [2], polarography [3], capillary electrophoresis 
[4,5], chemiluminescence [6], HPLC [7-8], and potentiometric titration [9]. Of course, 
the above mentioned techniques are sensitive but expensive. Spectrophotometry is the 
technique of choice even today due to its inherent simplicity. It is frequently used in 
the laboratories of the developing countries to overcome versatile analytical problems. 
In the literature, few spectrophotometric methods have been reported for its 
determination. Lisinopril has'been determined in the visible region based on the 
reaction with sodium hypochlorite and phenylhydrazine [10], chloranil [11], dichlone 
[11], acetylacetone and formaldehyde [11], 1,2-napthoquinonc-4-sulphonic acid [12] 
and 2,4,6-trinitrobenzoic acid [13]. Panzade and coworkers [14] have reported a UV 
spectrophotometric method for the quantification of lisinopril at 205 nm. Beer's law 
was obeyed in the concentration range of 3-30 jig mL"'.'' A derivative 
spectrophotometric procedure [15] for the simultaneous determination of amlodipine 
and lisinopril was developed. In this method, the drug was extracted in 0.1 M MCI and 
zero crossing point technique was employed to determine the amounts of individual 
drugs in the combined preparations. Jain and coworkers [16] have discussed two 
1 2 2 
procedures for simultaneous determination of amlodipine besylate and lisinopril in 
tablets. The first method was based on the development of two equations for area 
calculation of curve at two wavelength regions. The second method employed 
multicomponerit mode of analysis over the range 300-190 imi using four sampling 
points 300, 271, 242 and • 213 nm. The lisinopril was also determined in 
pharmaceutical formulations using ratio spectra derivative spectrophotometry [17] 
and derivative spectrophotometry [3,10,17,18], The literature is still poor with regard 
to the kinetic spectrophotometric method of analysis. As far as our knowledge is 
concerned, no kinetic spectrophotometric method is reported for the assay of 
lisinopril. 
Minhydrin is a well-established reagent for the determination of certain 
amines, amino acids and thiophenes [19]. It has been extensively used in the 
determination of the compounds of pharmaceutical importance and in the kinetic 
studies [20-22]. J. Bartos [23] has introduced ascorbic acid as a sensitive reagent for 
the specific determination of aliphatic amines in N, N'-dimethylformamide (DMF) 
medium without elucidating the mechanism of the reaction. In this laboratory, we 
have used ascorbic acid as a reagent for the determination of a pharmaceutical 
possessing aliphatic amino group and proposed a reaction mechanism after an 
appropriate study. [24] 
In this chapter, two sensitive spectrophotometric methods for the 
0 
determination of lisinopril in DMF medium have been described. The first method is 
based on the reaction of lisinopril with ninhydrin at room temperature for which a 
kinetic approach has been adopted. The second method is based on the reaction of 
1 2 3 
lisinopril with ascorbic acid. The proposed methods have been succ^sstully applied to 
the determination of lisinopril in pharmaceutical formulations. 
Experimental 
Apparatus 
Bausch and Lomb Spectronic 20D"^  spectrophotometer (iMilton Roy, USA) 
was used for measurement. 
Reagents and Materials 
DMF (spectroscopy grade) and ascorbic acid (AR-grade) w^re obtained j&om 
S.D. Fine Chemicals, India. Ninhydrin was purchased from Merck-Schuchardt, 
Gennany. 0.1% solution of lisinopril was prepared by dissolving mg of pure 
lisinopril (M/s. Zydus Cadila Healthcare Limited, India) in 10 mL of doubly distilled 
water into a 100 mL volumetric flask and finally made upto the mark with DMF. 
Further dilutions were made according to the need using 9 : 1 jtiixture of DMF : 
Water. 2% ninhydrin solution was prepared in DMF. Ascorbic acid solution (0.2%) 
was prepared by dissolving 100 mg in 0.5 mL of distilled water in a 50 mL standard 
flask and completing the volume with DMF. 
Preparation of the Acid Induced Degradation Product 
50 mg of lisinopril dihydratc was transferred into a conical flask and then 50 
mL of 50% H2SO4 was added. It was refluxed for 2 h at lOO'^ C. After cooling, the 
solution was neutralized with calcium carbonate and filtered. I^he filtrate was 
evaporated to dryness and the residue was tested for complete degradation using TLC 
plate coated with silica gel-G and chloroform-ethyl acetate-acetic acid (10:3:2 v/v) as 
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mobile phase. A single spot was observed at Rf = 0.17 whereas no spot was detected 
at Rf = 0.31 corresponding to lisinopril dihydrate. 
Recommended Procedures 
Ninhydrin method Aliquots of 0.05% lisinopril corresponding to 50-250 ng were 
transferred into a series of 5 mL standard volumetric flasks. To each flask, 1.7 mL of 
2% ninhydrin solution was added and diluted to volume with DMF. The contents of 
the mixture were mixed well and increase in absorbance at 595 nm was recorded as a 
function of time against the reagent blank at room temperature. The initial rate of 
reaction at different concentration was calculated from the initial slope of absorbance 
time curve. The calibration curves were constructed by plotting (i) logarithm of 
initial-rate of reaction versus logarithm of molar concentration, (ii) rate-constant 
versus final concentration and (iii) absorbance measured at a fixed-time of 10 minute 
versus final concentration of lisinopril. 
Ascorbic acid method Into a series of boiling tubes, increasing volumes of 0.05% 
lisinopril were quantitatively transferred so as to contain the drug within the 
concentration range of 5-50 |ig mL"^ To each tube, 2 mL of ascorbic acid solution 
(0.2%) was added and volumes were maintained to 5 mL with DMF. The solutions 
were heated on a water bath at 100 ±1°C for 15 minutes. The solutions were cooled at 
room temperature. The contents of each tube were transferred to a 10 mL standard 
flasks and completed to volume with DMF. The absorbances were measured at 530 
nm against the reagent blank prepared simultaneously within the stability period of 3 
h. The calibration curve was constructed by plotting the absorbance versus final 
concentration of the lisinopril. The content of the drug was computed either from 
calibration curve or regression equation. 
1 2 5 
Analysis of pharmaceutical formulations 10 tablets equivalent to 100 mg of the 
lisinopril were powdered and transferred into a small flask with 50 mL methanol and 
stirred. The extract was filtered into 100 mL volumetric flask and diluted to volume 
with methanol. The filtrate was evaporated to dryness. The residue was dissolved with 
10 mL distilled water and diluted to 100 mL with DMF. The assay of lisinopril was 
completed following the recommended procedures. 
Results and Discussion 
It has been suggested [28] that ninhydrin was converted to o-
carboxyphenylglyoxal in alkaline medium which would reduce ninhydrin to 2-
hydroxyindan-I,3-dione. In the present study, it combines with -NH2 group of 
lisinopril to form amino derivative which further undergoes condensation with 
ninhydrin to give diketohydrindylindene-diketohydrindamine which absorbs 
maximally at 595 nm (Fig. 4.1). 
Lisinopril, as a primary amine, reacts with ascorbic acid in DMF medium to 
produce a coloured product which absorbed maximally at 530 nm (Fig. 4.1). Under 
the specified experimental conditions, ascorbic acid undergoes oxidation resulting in 
the formation of dchydroascorbic acid [29]. The carbonyl group of dehydroascorbate 
reacts with -NH2 group of lisinopril to form a purple coloured condensation product. 
By analogy to previous report [24], the reaction is proposed to proceed as shown in 
scheme 4. L 
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Fig. 4.1 Absorption spectra of reaction products (a, lisinopril -
ninhydrin and c, lisinopril - ascorbic acid) and their reagent 
blanks (b and d, respectively). 
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Optimization of reaction variables 
The reaction between lisinopril and ninhydrin in DMF resulted in the 
formation of diketohydrindylindene-diketohydrindamine. At room temperature 
(~25°C), the intensity of colour increased with time and became stable after 45 minute 
of reagent mixing. The effect of ninhydrin concentration on reaction rate was 
investigated using 0.8-2.4 mL of 2.0% ninhydrin. It was found that increasing the 
volume of 2.0% ninhydrin solution would increase the absorbance of the reaction 
product upto 1.5 mL, after which further increase in the volume of ninhydrin resulted 
in no change in the absorbance of reaction product. Thus, 1.7 mL of 2.0% ninhydrin 
was adopted as the most suitable volume for maximum absorbancc. 
The reaction of lisinopril and ascorbic acid in DMF medium involves two 
variables i.e. heating time and concentration of ascorbic acid. To study the effect of 
heating time for ascorbic acid method, 500 ^g of lisinorpil was mixed with 2.0 mL of 
0.2% ascorbic acid in a boiling tube and heated on a water bath at 100 ± 1°C. The 
absorbance was measured at 530 nm as a function of time. It was observed (Fig.4.2) 
that the absorbance remained constant between 14 and 21 minute of heating. Thus, 16 
minute of healing time was selected as an optimum value. The inllucnce of volume of 
0.2% ascorbic acid was critically examined. It is evident from Fig. 4.3 that the 
maximum absorbance was obtained with 1.5 mL and above this \'oIumc, the 
/ 
absorbance remained unaffected. Therefore, 2 mL of 0.2% ascorbic acid was used 
throughout the experiment. 
The stoichiometric ratio between ninhydrin and lisinopril was established by 
the limiting logarithmic method using two sets of the experiments. In the first set, 
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Fig.4.2 Effect of heating time on the lisinopril - ascorbic acid reaction 
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Fig.4.3 Effect of volume of 0.2% ascorbic acid on the lisinopril 
ascorbic acid reaction after 16 minutes of heating-
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lisinopril concentration was varied keeping ninhydrin concentration constant and vice 
versa in the second set of experiment The logarithms of the absorbance thus obtained 
were plotted against the respective logarithms of the molar concentrations. The slopes 
of the two straiglit lines were obtained to be unity in each case which indicated the 
combining molar ratio between lisinopril and ninhydrin is 1:1 (Fig. 4.4). 
Kinetic Study Using Ninhydrin 
Initial-rate method: The initial rates of the reaction were determined from the 
measurements of the slopes of the initial tangents to the absorbance - time curves 
(Fig.4.5). The order with respect to lismopril was ascertained by studying the reaction 
at different concentrations of lisinopril keeping a constant concentration of ninhydrin. 
For each run, a plot of log AJAoo-A^ versus time is a straight line confirming the first 
order reaction. The first order rate constants were evaluated from the slopes of the 
plots of log Aoo/Ac-At versus time. All subsequent investigations were also performed 
with different concentrations of ninhydrin with a fixed concentration of lisinopril. TThe 
plot of log Aoo/A«)-At versus time also indicated a first order kinetics with respect to 
ninhydrin concentration. 
Under the optimized experimental parameters, ninhydrin concentration was 
used in excess in order to work out pseudo-first order condition. Therefore, the initial 
rate of reaction under pseudo-first order conditions would obey the following 
equation: 
Rate = AA/At = k'C" 
Where, k' is the pseudo-first order rate constant, C is the concentration of lisinopril, n 
is the order of reaction. The above equation may be written in logarithmic form as 
1 3 2 
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Fig, 4.4 Determination of the stoichiometric ratio between lisinopril and 
ninhydrin' by the limiting logarithmic method. ( • ) Constant 
ninhydrin concentration and variable lisinopril concentrations, (o) 
Constant lisinopril concentration and variable ninhydrin 
concentrations. 
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Fig. 4.5 Absorbance-time curve for the varying concentrations of lisinopril 
and fixed concentration of ninhydrin (3.82 xlO"^ M). (•) 2.26 xlO"^ 
M; (• ) 4.53 xlO"^ M; (A) 6.80 xlO"" M; (T) 9.06 xlO"' M; (•) 
11.33 xlO"^ M. 
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Log rate = log k' + n log C 
The slope, intercept and correlation coefficient were evaluated by linear 
regression analysis of calibration data (Table 4.1). The regression of log rate versus 
log C gave a linear regression equation, 
Log rate = 3.078 + 1,076 log C 
The value of n in the regression equation also indicated the first order reaction 
with respect to lisinopril concentration. The calibration curve (Fig, 4.6) constructed by 
plotting log rate versus log molar concentration of lisinopril showed a linear 
relationship over the concentration range of 10-50 |xg niL"^ 
Ratc-constant method: Under pseudo-first order condition, the rate constants 
corresponding to different concentrations of lisinopril were calculated from the slopes 
of log Aoo/Aoo-At versus time and are summarized in Table 4.2. The calibration graph 
(Fig. 4.7) was constructed by plotting rate constant against the lisinopril concentration 
which showed a linear response over the concentration range of 10-40 jxg mL"^ The 
regression equation, correlation coefficient, detection limit, variance and standard 
analytical error are presented in Table 4.1, 
Fixed time method: At a preselected fixed time, the absorbance was measured at 595 
nm against reagent blank. The calibration graphs of absorbance versus initial 
concentration of lisinopril were established at fixed time of 4, 6, 8, 10 and 12 minute 
(Fig.4.8). Under the established working condition, regression equations were 
developed and important analytical parameters have been calculated (Table 4.3). It is 
evident from Table 4.3 that the most acceptable values of correlation coefficient, 
Table 4.1 Statistical data of the proposed procedures. 
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Parameter Kinetic methods using ninhydrin Ascorbic acid 
method 
Initial rate Rate constant 
Linear dynamic range ()ig mL"') 10-50 10^0 5 - 5 0 
Regression data: 
Intercept {a) 3.078 8.563x10"^ 1.062 X 10-^  
Sa 0.146 L414X10- 7.828x10"^ 
i fSa 0312 3.04 J xJO"^  OA 52 
Slope {h) 1.076 1.083x10-3 1.023X 10-^  
Sb 0.292 6.334x10"' 1.696x10"^ 
±tSb 0.622 1.352x10"^ 3.295x10"^ 
Correlation coefficient (r) 0.9978 0.9972 0.9992 
Variance {So) 7.312x10-' 1.648x10-^ 7.234X 10-^  
Limit of detection (|ig mL~ )^ 0.118 2.839 ' 0:349 
SAE 3.491x10"^ 5.724x10"^ 3.472x10"' 
1 3 6 
-1.0 n 
^.6 -4.5 -4.4 -4.3 -4.2 -AA 
Log of molar concentration of llslnopril 
-4.0 -3.9 
Fig. 4.6 A plot of initial rate of reaction vs molar coricentration of 
lisinopril in lisinopril - ninhydrin method illustrating the 
linearity of the assay over the calibration ran^e. 
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Table 4.2 Values of rate constant (k) calculated from slopes of log Aoo/Aoo-At 
versus time graphs at 595 nm. 
k (min"^) Concentration of lisinopril fig mL"^ 
9.576x10"' 
10.863x10-2 20 
11.708x10"^ 30 
12.888xl0~^ 40 
138 
0.125 n 
0.090 
Concentration.of lisinopril in ^g mL'^ 
Fig. 4.7 A plot of rate constant vs final concentralion of lisinopril 
and ninhydrin method illustrating the linearity of the assay 
over the calibration range. 
1 3 9 
0.7 -
10 20 30 40 50 60 
Concentration of lisinopril in ^g mL' 
Fig. 4.8 A plot of absorbance vs concentration at a fixed time of 10 
minutes in the reaction between lisinopril and ninhydrin 
illustrating the linearity of the assay over the calibration 
range 
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Table 4.3 Calibration equations, precision and accuracy at different fixed times for 
lisinopril concentrations in the range of 10-50 |ag mL"^  
Fixed time methods 
Parameter 
4 min 6 min 8 min 10 min 12 min 
Calibration A=5.09xl0' A=7.68xl0' A=9.8xl0-^ A=l.10x10- A=1.21xl0-
Equation 3 ^ C- C-1.58x10'^ ^ C- ^ C-
C-1.97x10'^ 1.72x10"^ 1.02x10"^ 6.8x10'^ 
Correlation r = 0.9887 r = 0.9958 r = 0.9995 r = 0.9996 r = 0.9995 
coefficient 
±lSa 3.0 X 10-^  2.76 X 10-^ 1.24x10"^ 1.19x10-^ 1.50x10"^ 
±lSb 9.49 X 10"^ 8.72x10^ 3.91x10"^ 3.75 X 10"* 4.75x10"^ 
Molar 1.876 X 10^  3.090 X 10^  4.01x10^ 4.70 X 10^  5.30 X 1 0 ^ 
absorptivity 
(1 mol"' cm" 
/ 
Detection 5.63 3.43 3.81 1.03 1.38 
limit 
(Mg mL"') 
Variance 1.98 X 10^ 1.68 X 10"* 3.36 x 1 0 ' ^ 3.09 X 10-^  6.59 X 10"^ 
S.D. I.4I xlO-^ 1.29 xlO'^' 5.8x10-^ 5.56x10-^ 8.12x10-^ 
SAE 0.0063 0.0058 0.0023 0.0025 0.0036 
Z iSa = Confidence limit for inierccpl. + tSb = Confidence 
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detection limit and variance were obtained at a fixed time of 10 minute Therefore, the 
fixed time of 10 min was utilized for assay of lisinopril concentration. 
Ascorbic acid method: Under the optimum experimental conditions, the linear 
calibration graph was obtained over the concentration range 5-50 ^g mL'^ (Fig.4.9). 
The calibration data were fitted by least square treatment and the corresponding 
calibration equation along with the relevant analytical parameters are summarized in 
Table 4.1. 
Under the optimum experimental conditions, the values of slopes of the 
regression equations of the proposed methods indicate good sensitivity. . The small 
values of the variance speak about the negligible scattering of the calibration data 
points around the line of regressions for all the proposed procedures. The high values 
of correlation coefficients obtained for regression equations exhibit good linearity of 
the methods. The significance of correlation coefficients was evaluated by calculating 
the /-values using the following formula [25]. 
The calculated values were found to be 26.07, 23.10, 70.68 and 55.87 for 
initial-rate, rate-constant, fixed-time and ascorbic acid methods, respectively. Thus, it 
can be concluded that there is significant relationship between the concentration of 
lisinopril and the variables used in the development of regression equations. 
To check the precision as well as accuracy of the proposed methods, 
independent repeatability studies were performed with six repetitions for each 
method. The results are summarized in Table 4.4. The obtained data show that the 
methods are reproducible as well as accurate. 
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Fig. 4.9 A typical calibration curve for absorbance vs concentration 
of lisinopril in the reaction between lisinopril and ascorbic 
acid. 
143 
Table 4.4 Test of precision of the proposed procedures. 
Methods Amount taken Amount found Recovery ± p-value 
(fig mL" )^ (Hg mL"*) ±S.D.° RSD (%)" 
Kinetic method 
Initial rate 30 30.52 ± 0.53 101.74 ±1.74 0.217 0.558 
Rate constant 30 30.20 ±0.37 100.68 ±1-23 0.151 0.322 
Fixed time 
\ 
30 30.22 ± 0.35 100.74 ±1.16 0.143 0.305 
Ascorbic acid 25 24.95 ±0.18 99.78 ±0.74 0.075 0.193 
° Six independent analyses. 
^ SAE, Standard analytical error, r-value (Df = 5) is 2.015 [27]. 
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The developed methods were successfully applied on the commercial dosage 
forms. The accuracy of the proposed methods was confirmed by the standard addition 
method as well as by the comparative studies of the recoveries with that of the 
reported method using point hypothesis (Table 4.5 and 4.6). The recovery, standard 
deviation and the %RSD are satisfactory. The paired lvalues as well as variance ratio 
F-test confirm that the two methods (proposed and reference) compared are not 
significantly different; encouraging the applicability of the developed methods for the 
routine analysis of lisinopril in the dosage forms. The interval hypothesis tests [26] 
have also been performed to compare the results of the proposed procedures (initial-
rate, rate-constant, fixed-time or ascorbic acid) with those of reference method at 95% 
confidence level. In pharmaceutical analysis, a bias of ±2% is permissible. The results 
(Table 4.7) show that the data are within the limit of the interval at 95% confidence 
level. 
As far as the selectivity of the method is concerned, the kinetic approach based 
on the reaction of lisinopril - ninhydrin was found to be highly selective for the 
determination of lisinopril at 25°C. The acidic degradation product was found not to 
react significantly with ninhydrin in DMF medium at room temperature and is 
tolerable upto 90%. 
In fxjnclusion, though both the methods are suitable for the routine analysis of 
lisinopril in commercial dosage forms but the ascorbic acid method is economical in 
comparison to the ninhydrin method. However, the ninhydrin method is selective for 
lisinopril and is suitable for the analysis of lisinopril in pure as well as commercial 
dosage forms in the presence of its acidic degradation product. 
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Introduction 
Captopril, l-[(2S)-3-mercapto-2-methyl propionylJ-L-proiine, is an 
angiotensin converting enzyme (ACE) inhibitor, which reduces peripheral resistance 
and lowers blood pressure. It is widely used in the hypertensive ailments and in 
congestive heart failure treatment [1]. Due to such crucial pharmacological 
importance, development of simple and accurate methods for the determination of 
captopril is desired. 
Several methods of analyses have been proposed for the determination of 
captopril which include high performance liquid chromatography [1,2], gas 
chromatography [3,4], capillary electrphoresis [5-7], flow injection analysis [8,9], 
polarography [10], atomic absorption spectrometry [11-13], fluorimetry [14], 
titrimetry [15] and polarimetry [16]. 
Titrimetry as well as spectrophotometry are the simplest analytical techniques 
extensively used in the drug standardization laboratories. Still a number of titrimetric 
and spectrophotometric assay methods can be found in different pharmacopoeias for 
the routine analysis of different types of drugs in pharmaceutical dosage forms due to 
their cost-effectiveness as well as easy to perform methodologies. 
Captopril was quantitatively determined in pharmaceutical preparations by 
measuring absorbance at 212 nm in the concentration range 5-50 i^g mL-^[17].The 
determination of captopril and hydrochlorothiazide in combined dosage forms was 
made on the basis of UV absorbance at 266.6 nm and 271 nm in 0.01 N acetic acid, 
respectively [18].The UV spectrophotometric methods have been utilized for 
quantification of captopril and hydrochlorothiazide in tablets by employing 
simultaneous equations using absorbances at their respective X max [19,20].Assay 
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procedures based on derivative spectrophotometry were developed for the 
determination of captopril alone or in combination with hydrochlorothiazide in tablets 
[21-23]. The literature survey revealed that the charge transfer complexation reactions 
of captopril with iodine monochloride [24], p - chloranilic acid [24], iodine [25] and 
7,7,8,8-tetracyanoquinodimethane [25] have also been utilized for its assay in bulk 
and dosage forms. Spectrophotometric methods for the assay of captopril have been 
discussed based on the oxidation of the drug with either FeCh or iodine .The indirect 
quantitation of the product was carried out at 750, 523, 351 and 620 nm for 
ferroferricyanide [26], ferrobipyridylj residual iodine and residual iodine starch 
complex [27], respectively. It has also been determined spectrophotometrically by 
employing the reaction of the drug with carbon disulphide in alkaline medium with 
the formation of dithiocarbamate; then subsequent chelation with divalent metal ions 
[28]. A number of other spectrophotometric methods have been reported in the 
literature based on the reaction of the drug with Folin - ciocalteu reagent [29], 4,4' -
dithvo-dipyridine [30], metol - Cr (VI) [31], acetic acid and acetic anhydride [32], 
dichlone [33], methylbenzothiazolinone hydrazone [34], molybdophosphoric acid 
[35], palladium (II) chloride [36], sodium nitrite [37] and tetrazolium blue [37]. 
A volumetric method for the determination of captopril using potassium iodate 
in hydrochloric acid medium has been mentioned in the USP [15]. 
Spectrophotometry, when couplcd with titrimetry for simultaneous volumetric-
spectrophotometric methods of determination, can be regarded as the simplest and 
least expensive simultaneous mode of determination which gives dual confirmations 
to the obtained results with slight modification at nominally elevated expense. 
Qureshi and co-workers have reported the same for the determination of certain 
cephalosporins [16]. The major drawback of the method is the assessment of 
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volumetric end-point. Earlier, potassium iodate have already been used for the 
determination of the same where the end-point of the titration was detected either by 
the decolorization of the pink color of iodine extracted in the CCI4 layer or by the 
decolorization of amaranth dye added before the expected end-point by excess of 
oxidant [17]. 
This chapter describes simultaneous volumetric-spectrophotometric methods 
for the determination of captopril in pure and dosage forms using potassium iodate as 
oxidant in HCl medium. Amaranth is used as indicator to detect the end-point of 
titration in the aqueous layer. The iodine formed durin titration is quantitatively 
extracted in CCI4 and subsequently determined spectrophotometrically at 510 nm. 
Experimental 
Apparatus 
A Bausch and Lomb Spectronic 200"^ spectrophotometer (Milton Roy, USA) 
was used for the spectral runs and absorbance measurements. Microburette of 
appropriate capacity was purchased from J-Sil Glassworks, India. 
Reagents and Materials 
0.2% captopril solution was prepared by dissolving 200 mg of pure captopril 
(M/s. Wockhardt Ltd., India) in doubly distilled water into a 100 mL volumetric flask. 
0.0IM KIO3 (E. Merck, India) solution was prepared by following a standard method 
[15]. 5M HCl solution was prepared by appropriate dilution of 35% supplied HCl (Ii. 
Merck). CCI4 was purchased from E. Merck. 0.2% aqueous stock solution of 
amaranth (Hi-Media, India) was also prepared and diluted further according to the 
need. 
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General procedure 
Aliquots of suitable volumes of standard captopril solution (0.2%) in the 
concentration range of 120 - 520 |ig mL"^ were pipetted into a 25 mL separatory 
funnel followed by 2 mL of 5M HCl and 5 mL of CCI4 . The captopril content in the 
mixture was titrated against O.OIM KIO3 with intermittent vigorous shaking, 2 - 4 
drops of 0.02% amaranth was added before the expected end-point and the titration 
was continued with the gentle swirling. The end-point was detected by a colour 
change of dye from deep red to pale yellow in the aqueous layer. After that, the whole 
content was further shaken by adding some more distilled water to facilitate the 
complete extraction of iodine in organic layer. The organic layer was separated well, 
passed through anhydrous sodium sulphate bed over a glass wool-plugged funnel. The 
absorbance of the coloured organic layer was recorded at 510 nm against the solvent 
blank. 
Analysis of pharmaceutical formulations 
8 tablets of Aceten, the only available commercial form of captopril in the 
local market, were finely powdered. It was dissolved in sufficient volume of doubly 
distilled water. The residue was filtered through Whatmann no. 42 filter paper into 
100 mL standard flask and the filtrate was diluted to 100 mL by repeated washing 
with distilled water. It was analyzed by the recommended procedures. 
Results and discussion 
Mechanism and stoichiometry of reaction 
The compounds containing -SH and - S - S - groups are oxidized by mild 
oxidants. -SH groups are quantitatively oxidized to sulphonic acid (-RSO3H) [18]. 
Captopril bears a -SH group in its moiety. In the proposed method, -SH group of 
captopril is oxidized to -SO3H group whereas lOs" is reduced to ICl, which may be 
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regarded as the reaction at the equivalence point but without any color change. The 
reaction can be summarized as follows (step I): 
H 
I 
\ / 
C 
o 
> H 
C—SH + 3 H 2 O 
H 
V X \ i 
H 
I . - C H a 
C H 
, .COOH 
> H 
C—SO3H +6H' '+6e" 
H 
x 2 
l03'-{-Cr'f'6H^ + 4e- la+SHzO x 3 
The above equation shows that the oxidation of 1 mol of -SH group to -SO311 
is a six electron transfer process while the reduction of 10date (lOs") to iodine 
monochloride (ICl) is only a four electron transfer process. Thus the stoichiometric 
value calculated theoretically should be 2 mol of -SH to 3 mol of lOj" (1 : 1.5) which 
is inconsistent with the experimental value . However, the system still involves more 
IO3" to make the end-point visible due to its reduction to ICl and finally to free iodine. 
This can be described in step II reaction as follows; 
REDUCTION + IO3 + 6H + 4 e 
ICl 
DISSOCIATION 
ICl + 3 H2O 
r + CI 
r + HoO 
5 HOI 
HOI + H"^ 
I2 + 103- + H" + 2 H2O 
In this step, an over consumption of IO3" takes place [20], thereby increasing the mole 
ratio of lO^" from 1.5 to 2.0 mol, which is consistent with the experimentally 
observed stoichiometry of 1 mol of -SH to 2 mol of IDs", and hence, a stable dark 
pink color of free iodine is obtained in organic layer. 
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Optimization of reaction variables 
Being a volumetric method followed by spectrophotometry, the proposed 
method requires the optimization of the volume of 5M HCl to maintain the acidic 
nature of the medium. In the proposed procedure, the effect of the volume of 5M HCl 
was examined, employing a fixed concentration of captopril which was titrated with 
0.0 IM KIO3. The extracted iodine in the organic layer was measured 
spectrophotometrically at 510 nm. The coloured organic layer showed a constant 
absorbance above 1.75 mL and therefore, 2 mL of 5M HCl was used throughout the 
experimental work (Fig.5.1). 
Study of interferences 
The proposed method was found to be selective for the determination of 
captopril in the presence of common excepients of formulations. The study of the 
interference has been done by adding common excepients into a fixed concentration 
of captopril. The results are summarized in table 5.1. 
Analytical data 
Under the optimum experimental conditions, a linear relationship between 
volume of 0.0IM KIO3 (or absorbance) and concentration of captopril was obtained 
over the concentration range 120 - 520 i^g mL"' (Fig. 5.2a & 5.2b). The calibration 
data were fitted by least square treatment to obtain the regression equations A = 5.97 
x 10"^  + 1.76 X 10"^  (r = 0.9981) and V (mL) = 1.09 x 10"^  + 2.25 x 10"^  (r = 0.9985) 
for spectrophotometric and volumetric methods, respectively. The correlation 
coefficients (r) obtained indicated good linearity of both the calibration graphs. The 
standard deviations of intercept and slope were calculated to be 1.56 x 10"^ and 3.72 x 
10"^  for spectrophotometric procedure whereas 1.74 x 10"^ and 4.15 x 10"^  for 
1 5 7 
0.78 -
2 3 
Volume o f 5M HCI 
Fig. 5.1 A plot for the optimization of acid 
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Table 5.1 Investigation of the tolerance limits of various excepients. 
Excepients Tolerance limit* (mg) 
Glucose 7.5 
Lactose 2.5 
Fructose 7.5 
Maltose 10.0 
Starch 5.0 
• The concentration of captoprjl is 200 (ig mU 
1 5 9 
600 
Concentration of drug in |ig ml" 
Fig. 5.2a Calibration graph for spectrophotometric method 
1 6 0 
600 
Concentration of drug in ^g ml 
r1 
Fig. 5.2b Calibration graph for volumetric method 
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volumetric method. The confidence intervals of intercepts at 95% confidence level 
were found to be 5.97 x 10"^  ± 2.83 x 10"^ and 1.09 x 10"^  ± 3.15 x 10"^  for 
spectrophotometric and volumetric methods, respectively, which confirm that they are 
not different from zero. The confidence intervals of slopes at 95% confidence level 
were found to be 1.76 x 10"^  ± 6.74 x and 2.25 x 10"^  ± 7.61 x 10"^  for 
spectrophotometric and volumetric methods, respectively. 
The repeatability of the proposed methods was evaluated by the repeated 
analyses at two different concentration levels. The results are summarized in table 5.2. 
The values for standard deviation recovery (%), relative standard deviation and 
standard analytical error can be considered to be satisfactory. 
The accuracy of the proposed procedures was investigated by the standard 
addition method. The recoveries obtained after the analysis of the samples prepared 
by adding certain known amount of pure drug in the formulation are in good 
agreement to the total concentration. The recovery was evaluated by dividing the 
intercept with slope value of the line of linear regression of the standard addition as 
well as by the extrapolation of the same line of best fit (Fig. 5.3a, 5.3b and table 5.3) 
[21]. The result obtained by both the methods, are in mutually good agreement. The 
standard deviation of extrapolation (SXE) was calculated from the fomiula [21]. 
= -
1 . 7 ' 
I'inally, the linearity of the line of regression of standard addition technique 
can be visualized by the values of the correlation coefficients (table 5.3). 
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Fig.5.3a Standard addition method for spectrophotometric procedure 
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Fig.5.3b Standard addition method for volumetric procedure 
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As far as the application of the proposed procedure is concerned, it has been 
successfully applied on the conmiercial dosage form, Aceten, without significant 
interference from the common excepients of the formulation. The comparison of the 
results of the proposed methods with those of reference method using point and 
interval hypotheses [22] has confirmed that there is no significant difference between 
the methods compared. All the t- and F-values are less than the tabulated values, 
(table 5.4) while the limits of intervals, as per the requirement of pharmaceutical 
analysis, are within ±2%. The results are summarized in table 5.5, 
In conclusion, the proposed simultaneous volumetric-spectrophotometric 
method is simple, economical and reproducible and can be adopted for the routine 
analysis of captopril in bulk and dosage forms. 
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Table 5.5 Comparative statistical analysis of the determination of captopril in Aceten 
tablets by the proposed and reference methods using interval hypothesis. 
95% confidence intervals (Interval hypothesis) 
Spectrophotometric method Volumetric method 
Lower limU(0L)° Upper limit (Ouf Lower limit (61)° Upper limit(60)° 
0.9975 1.0041 0.9909 1.0044 
A, In pharmaceutical analysis , a bias of ± 2% ( 9L = 0.98 , OU = 1.02 ) is acccplable. 
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